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Technological innovation at the nanometer scale has the potential to improve a wide 
range of applications, including energy storage, sensing of environmental and medical 
signals, and targeted drug delivery. A key challenge in this area is the ability to create 
complex structures at the nanometer scale. Difficulties in meeting this challenge using 
traditional fabrication methods have prompted interest in biological processes, which 
provide inspiration for complex structural organization at nanometer to micrometer 
length scales from self-assembling components produced inexpensively from 
common materials.  
From that perspective, a system of targeted modifications to the primary 
amino acid structure of Tobacco mosaic virus (TMV) capsid protein (CP) has been 
  
developed that induces new self-assembling behaviors to produce nanometer-scale 
particles with novel architectures. TMV CPs contain several negatively charged 
carboxylate residues which interact repulsively with those of adjacent CP subunits to 
destabilize the assembled TMV particle. Here, the replacement of these negatively 
charged carboxylate residues with neutrally charged or positively charged residues 
results in the spontaneous assembly of bacterially expressed CP into TMV virus-like 
particles (VLPs) with a range of environmental stabilities and morphologies and 
which can be engineered to attach perpendicularly to surfaces and to display 
functional molecular patterns such as target-binding peptide chains or chemical 
groups for attachment of functional targets.  
In addition, the distinct electrostatic surface charges of these CP variants 
enable the higher-level coassembly of TMV and VLP into continuous rod-shaped 
nanoparticles with longitudinally segregated distribution of functionalities and surface 
properties. Furthermore, the unique, novel, environmentally responsive assembly and 
disassembly behaviors of the modified CPs are shown to act as simple mechanisms to 
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Chapter 1: Introduction 
 Background and Motivation 1.1.
 The core motivation of this research project is twofold: (I) to improve upon 
the proven potential of Tobacco mosaic virus to function as a self-assembling, well 
organized nanoparticle and (II) to use TMV as a model system to better understand 
how to design and control the self-assembly of protein-based nanomaterials. This 
motivation arose from (i) the increasing awareness of the utility of nanostructured 
materials for a wide array of applications, (ii) understanding of the advantages that 
naturally occurring, biologically based materials and methods provide for the creation 
of nanomaterials, and (iii) recognition that viruses in particular are an adaptable and 
fertile model for nanoparticle production. This section will attempt to establish these 
ideas in some more detail. 
 Advantages and applications of nanostructured materials 1.1.1.
 Controllable, hierarchical self-assembly of complex architectures at 
nanometer to micrometer length scales is an important, and potentially revolutionary, 
capability promised by nanotechnology. The development of successful methods for 
producing reliable and consistent results toward this goal will have profound 
implications for advancements in diverse technological areas such as the harvesting, 
conversion and storage of energy for clean and renewable energy usage [1-4], sensing 
of environmental and medical signals [5, 6], and targeted drug and medical imaging 





The promised benefits of nanotechnology, and of the benefits afforded by 
nanomaterials, rest on the potential improvements to existing functions or the creation 
of completely new functions made possible by the nanometer length scales that 
characterize them. Nanometer-scale structures exist at the extreme end of the trend 
toward miniaturization that has dramatically improved the performance of 
technologies in recent decades. Radical miniaturization of functional device 
components reduces the overall footprint necessary for those components. This can 
reduce the size and of the device itself, improving portability and storage 
requirements, which lead to greater availability of the technology. At the same time, 
detrimental impacts to the environment can be alleviated by reducing both the energy 
requirements of the device while it is in use as well as the amount of waste associated 
with its disposal. 
Targeted drug delivery is one example of a promising technology being made 
possible by the development of nano- to micrometer scale structures that may 
radically improve treatments for costly and tragic diseases such as cancer. One of the 
most effective treatments for some forms of cancer involves the administration of 
chemotherapeutic agents to the patient which are intended to kill or stop the growth of 
cancer cells which may have metastasized throughout the body. Such drugs inevitably 
have harmful effects on the patient’s healthy cells, so treatment requires finding a 
compromise between the goals of attacking the cancer and not harming the patient. 
Targeted drug delivery seeks to improve the result of this compromise by delivering 
the chemotherapeutic agents to the cancer cells in a targeted manner, improving 





effects that reduce the patient’s quality of life. The drug delivery vehicles involved in 
this type of treatment need to be able to contain the chemotherapeutic agent while 
displaying features that will cause their preferential uptake by the cancer cells, all 
while remaining small enough to pass through capillaries and remain in circulation 
long enough for eventual uptake by the cancer cells. This last requirement 
necessitates the use of particles in the low micrometer scale at the most, but other 
considerations can make smaller, nanometer-scale particles preferable, including their 
greater uptake by target cells, ability to cross the blood-brain barrier, and faster drug 
release profile [11]. In addition, the ability to precisely control the properties of these 
particles can dramatically affect their effectiveness. The physical and chemical 
properties of the particle surface are crucially important to the targeting of cells, 
influencing biodistribution and accumulation profiles through cellular uptake, 
prolonging circulation time, and determining immune system clearance or evasion 
[11]. Establishing greater control over these factors, including the nanoscale 
patterning of particle surface properties, appears to be a crucial factor in the 
therapeutic efficacy of the platform. 
Improved control over the patterning and architecture of nanoscale structures 
and materials has many other potentially revolutionary applications. Many useful 
biochemical processes that occur naturally within cells involve pathways of chemical 
reactions catalyzed by enzymes. Successfully transferring these complex networks 
into in vitro environments for energy harvesting and conversion, for chemical and 
pharmaceutical synthesis, or for isolation and study is an ongoing project for 





enzyme in vivo often depend on their confinement and spatial arrangement at the 
submicron scale to effectively couple enzymatic reaction together through control of 
the concentration, diffusion, stability and channeling of the enzymes, substrates, 
reaction-intermediates, cofactors and products. The form of this patterning can be a 
two-dimensional arrangement along membranes surfaces [12, 13] or a more complex 
three-dimensional compartmentalization within proteinaceous [14] or membrane-
based capsules and vesicles. The harnessing and study these enzyme cascades in an in 
vitro environment would benefit immensely from new materials that could be used to 
control the spatial patterning and arrangement of enzymes at nanometer scales [15]. 
The essential requirement of these approaches is the ability to control the 
three-dimensional organization of material components at a micro- to nanometer scale 
in a way that allows for scalable production of these materials. Improvements in 
efficiency, power, novelty, and utility in a variety of other application fields are 
promised by the development of materials and method allowing precise control of 
complex nanoscale patterns and architectures.  
 Strategies for generating micro- and nanostructures 1.1.2.
 Biology offers unique solutions to current needs in nanoscale design and 
application. The existence of functional nanoscale structures within living biological 
systems provides a natural starting point for the generation of new types of 
nanostructured materials with tailored functions and properties in the lab or factory. 
Using biological molecules to create nanomaterials has the advantage all the 
preexisting machinery for the production of these molecules, the preexisting methods 





molecules to coassociate and organize themselves in a bottom-up manner to generate 
higher-order structures. Attempts to create these kinds of structures from non-
biological components need to solve or avoid these issues that have already been 
solved in biological systems, and all successful attempts do this in ways that are 
sometimes distinct from and at other times inspired by the biological solutions. A few 
of the non-biological components and methods for the creation of non-biological 
nanostructured materials are inorganic nanoparticles, polymers, carbon nanotubes, 
and dendrimers. 
Biological systems have developed an array of methods for solving problems 
and interacting with their environment at nanometer to micrometer length scales. 
Cells employ a diverse toolkit for accomplishing the activities necessary for 
continued existence, including fine-tuned recognition of target molecules, strong and 
reversible binding of those targets, chemical modification of molecular analytes 
through enzymatic processing, and systematic coupling of these modification through 
enzymatic chains which together enable them to perform such diverse tasks as 
pathogen recognition and elimination and harvesting of energy for further cell 
function. All of these tasks are accomplished in a “bottom-up” approach, through the 
assembly from simple monomeric units of macromolecular components with well-
defined structures, surface properties, and functionalities. This bottom-up fabrication 
method of nanoscale functional material is of particular interest for its potential use in 
the creation of materials and surfaces due to its often greater efficiency and scalability 





Bionanomaterials (nanostructured biomaterials): Nucleic acids, such as DNA, are 
being investigated as raw materials for the self-directed construction of complex but 
well defined nanoscale structures and even larger scale materials with regular 
nanoscale patterns, such as regular and repeated binding motifs. The use of nucleic 
acids as a structural building material for the construction of nanoscale materials is 
developing rapidly and is enabled by the structural features that allow them to 
function as the primary physical method of information storage in the natural world, 
namely the flexible yet structurally stable, arbitrarily long, covalently linked, single 
molecule backbones which routinely reach centimeters in length together with the 
non-covalent coupling mechanism between strands by extensive, sequence dependent, 
individual base-pairing events. The importance and ubiquity of nucleic acids have led 
to the development of reliable and relatively inexpensive chemical methods to 
synthesize oligonucleotides of arbitrary length and sequence as raw materials. Two 
primary approaches have emerged in the field of nucleic acid-based nanostructured 
materials, one using DNA alone as the basis for the creating rigid nanostructures, the 
other using non-nucleic-acid-based nanoparticles, which provide rigidity, coupled 
with DNA, which direct their arrangement and organization. 
The first approach uses the regular spacing of nucleotides along the DNA 
backbone and the sequence specificity of noncovalent hybridization of antiparallel 
DNA strands via Watons-Crick base-pairing interactions to direct the self-assembly 
of numerous DNA strands into complex architectures with well-defined geometries. 
The interaction of each component DNA strand with multiple other strands allows for 





flexibility of its 
components. This method 
has allowed for the 
creation of increasingly 
complex two-dimensional 
[18, 19] and three-
dimensional [20-22] 
structures founded on a 
hierarchical assembly 
process in which rigid 
tiles composed of multiple oligonucleotide strands self-assemble into larger structures 
by DNA hybridization of the unpaired “sticky ends” exposed at the tiles’ edges 
(Figure  1-1A, B). 
 In contrast to the hybridization of DNA tiles, which typically results in 
objects and materials with regular or periodic structure, DNA origami uses many 
short oligonucleotides to act as “staples” which cross-hybridize and tether distant 
sections of a much larger (multithousand-base long) DNA strand, inducing it to adopt 
some specific conformation. The assistance of computer-aided design software allows 
for the creation of complex two-dimensional [23] and three-dimensional [24-26] 
DNA origami structures (Figure  1-2). The structural complexity afforded by the 
method of DNA origami has several drawbacks. The conformational reactions require 
precise ion concentrations and very long annealing times (up to one week) and can 
Figure 1-1: DNA hybridization-based tiled structures. (A) 2D lattice based 
on a tessellation of a DNA tile consisting of nine oligonucleotides. 
Reprinted with permission from [18]. Copyright 2003. (B) 3D wireframe 
polyhedral built from DNA three-point star motifs, where shape depends 
on the intrinsic curvature and concentration of the tile. Reprinted with 








still result in low yields of properly 
folded conformations, necessitating 
further gel purification steps to obtain 
high quality samples [27]. 
The second approach uses 
surface-bound oligonucleotides to 
spatially arrange rigid nanoparticles. A 
typical method uses designed 
oligonucleotides with either 3ʹ or 5ʹ 
terminal thiol groups which are subsequently templated onto the surface of colloidal 
gold nanoparticles through gold-thiol interactions. Very dense oligonucleotide 
monolayers can be established on the nanoparticle surface when high ionic strength 
solutions, which can screen the mutually repulsive negative charges of the 
oligonucleotides, are employed [28]. Hybridization of the surface-bound 
oligonucleotides to those of adjacent nanoparticles can induce the formation of 
various superlattice structures, when spherical nanoparticles are used [29, 30], or 
alternative configurations by either controlling the controlling the templating of the 
oligonucleotides onto the nanoparticles [31]  or by using anisotropic nanoparticles 
[32]. 
Strategies for forming nanomaterials from protein  
 One of the most versatile classes of components in biology’s toolkit and a 
prime candidate source for bottom-up fabrication of novel functional materials are 
proteins, which accomplish diverse roles as structural scaffolds as cytoskeletal 
Figure 1-2: DNA hybridization-based origami 
structures. (A) 2D origami structures. Reprinted with 
permission from [23]. Copyright 2006. (B) Twisted 3D 
DNA Bundles and (C) curved DNA structures 





components and viral capsids, molecular recognition sensors as receptors and 
antibodies, and chemical processing catalysts as enzymes. Proteins represent a more 
complex class of materials than nucleic acids, and so their use as the foundation for 
the construction of nanostructured biomaterials has several advantages. While nucleic 
acids are generally comprised of a relatively small number of fundamental building 
blocks (A, C, G, T, and U ribo- and/or deoxyribonucleotides), which can limit the 
number of combinations and specificity of chemical features, limiting the material’s 
potential for complex functionality, proteins are built from a broader set of building 
blocks, twenty (or more) amino acids with a wider variety of physical and chemical 
properties. This gives protein a much larger set of possible combinations of 
sequences, expanding the structural and functional workspace/set of possible states. 
The specific nature of the 1° (amino-acid sequence) structure of the protein 
determines the 2° (local conformational folding), 3° (global conformational folding), 
and 4° (coassociation of multiple peptide chain) structure in complex but 
deterministic ways, the prediction of which is the focus of intense effort and continual 
improvement. This enhancement of possible structures and functions compared to 
nucleic acids is reflected in the broader set of roles naturally relegated to proteins in 
their native cellular and organismal environments. Additionally many of the distinct 
chemical groups present in the various amino acid side chains can be independently 
targeted for specific uses, making proteins more chemically tractable than nucleic 
acid-based nanostructures. Proteins are also extremely genetically tractable, as 
modification of the gene encoding the protein by uncomplicated and routine 





protein in any of numerous common cellular expression systems. Modifications to 
protein structure therefore benefit from the same processes that enable the generation 
of the raw materials for DNA-based nanostructures. This section will review some of 
the research into methods for creating nanomaterials from protein components. 
 Fusion proteins for symmetrical self-assembly: Some proteins naturally form 
symmetrically arranged complexes from multiple identical copies. Usually, these 
quaternary protein assemblies comprise dimers, trimers, tetramers, etc. which are 
assembled into regular polyhedral shapes, such as tetrahedrons, hexahedrons, 
octahedrons, dodecahedrons, and icosahedrons. A general method for combining the 
natural ability/tendency of proteins to self-assemble into small regular polyhedral in 
order to generate more complex nanostructured materials was described by Padilla et 
al. [33] wherein two proteins that separately form multimeric symmetrical assemblies 
with other copies of themselves are used to create a rigidly fused protein that will 
self-assemble with other copies of itself in more complex ways derived from the self-
associating tendencies of its components. Using this method, nanoscale protein cages 
[34] and a highly porous protein cube [35] were designed.  
Three-dimensional domain-swapped oligomers: The method of three-dimensional 
domain swapping involves replacing an individual structural domain from one protein 
monomer with the same domain from a second monomer. In this way the two 
monomers assemble together when the new domain of the first monomer associates 
with the second monomer to complete its native assembly. This method has been 
successfully utilized to design and construct new dimers and fibrous oligomers [36], 





Zn-SO4-encapsulating nanocage consisting of a domain-swapped cytochrome cb562 
dimer [39]. 
Self-assembling modules of designed coiled-coil peptides: Many protein-protein 
interactions involve associated domains of alpha-helical coiled coils. These 
interactions between amphipathic α-helices lead to a wide variety of protein 
assemblies [40]. Several researchers have incorporated these domains to guide the 
self-assembly of various nanostructured biomaterials, including a self-assembling 
cage from coiled-coil peptides [41] and self-assembling peptide nanotubes with a 
variety of predetermined inner channel diameters and chemistries from α-helical 
barrel building blocks [42]. The latter of these, the peptide nanotubes, displayed some 
tenability with respect to longitudinal assembly between the subunits and lateral 
associations between nanotubes [43]. Finally Sciore et al reported a simple, 
generalizable method for the assembly of protein cages from short de novo designed 
coiled-coil domains [44].  
Computationally designed self-assembling artificial proteins: Advances in structure 
prediction [45] and design principles for de novo proteins [46, 47] have enabled a 
general computational approach for the design of self-assembling protein structures 
[48, 49]. The approach involves the design of low-energy protein-protein interfaces 
combined with a symmetrical repetitive architecture to drive the assembly of large 
scale arrays of designed protein subunits using RosettaDesign calculations. Variation 
of the symmetric architecture can produce protein arrays extending in one, two, or 
three dimensions. …designed and produced a “self-assembling icosahedral nanocage 





icosahedral protein complexes from two-component 120-subunit proteins with 
atomic-level accuracy” [51]. In the latter, the researchers designed, produced, and 
experimentally characterized 120-subunit icosahedral protein nanostructures from 
two co-assembling components that were comparable in mass (1.8-2.8 MDa) and size 
(24-40nm diameter) to small viral capsids. [10 different designs, each with one of 
three different icosahedral architectures produced protein nanostructures closely 
matching computational models] These artificial proteins assemble in vitro from 
independently purified components and allows for the electrostatic charge-based 
packaging of small molecular cargo. 
All of this recent work in novel protein-based nanomaterials is an extension of 
the set of naturally occurring proteinaceous nanostructures developed through the 
evolutionary process of trial and error and employed as a fundamental component of 
all living systems. A remarkably successful and extensive refinement process has 
produced all of the examples of existing structural proteins found in the natural world. 
These diverse structural proteins exhibit a wide variety of finely-tuned capabilities 
and properties that can not only provide exemplary inspiration for entirely novel 
protein designs but can also act as the established foundation for the development of 
new proteinaceous nanomaterials through relatively minor alterations either pre- or 
posttranslation. 
 Viruses as bionanomaterials 1.1.3.
 One class of protein-based biological nanostructures that offer particular 
suitability as potential platforms for the creation of novel biomaterials is viruses. 





assembly of one or several viral proteins packaging a nucleic acid genome. Viruses 
take advantage of the structural, molecular recognition and functional capabilities of 
protein for the purposes of host cell recognition, cell invasion and infection, 
extracellular stability, and packaging and containment of a cargo load in the form of 
their RNA or DNA genome. This unique combination of properties has made viruses 
a productive foundation for the development of a wide range of engineered 
applications including targeted drug delivery [52-54], biosensing [55], and energy 
storage [56, 57]. What follows is a review of the literature that treats viruses as 
materials 
Several plant viruses have been investigated as nanoscale templates for the 
development of new materials and applications. Plant viruses share features that make 
them attractive as the basis for the fabrication of biomaterials. They are simple and 
often highly stable particles that self-assemble from defined protein subunits with 
remarkable uniformity of size and shape. The repetitive/iterative nature of the viral 
capsid makes it useful for the concentrated and organized display of functional groups 
in the form of native or engineered amino acid side chains, which can serve as 
functionalizing entities in their own right or as sites for chemical attachment of other 
molecules or sites for the nucleation of inorganic materials. The ability of viruses to 
self-assemble and to remain monodisperse in solution allows for the processing and 
analysis of these nanoparticles as a bulk material [58]. The three dimensional 
structure of many plant viruses is known, often to a high degree of atomic precision, 
allowing for the identification of functional groups available for targeting or the 





within or on the viral nanoparticle. These design alterations to the viral nanoparticles 
is made possible by the encoding of the viral nanoparticle’s component materials in 
its genome, allowing for the use of standard and well established methods of genetic 
modification. Finally, plant viruses can be produced relatively inexpensively and 
renewably at large scales [17].  
As is the case with viruses in general, plant viruses typically have one of two 
primary morphologies: icosahedral or helical. Viruses of each type are being 
investigated as biological scaffolds in materials applications. The two morphologies 
are characterized by different structural geometries and properties that can be useful 
for different applications. Icosahedral viruses have a large inner chamber enclosed on 
all sides by the capsid proteins that surround and protect the viral genome. This inner 
chamber provides a location for the loading and storage of cargo, such as therapeutic 
or imaging molecules. Many helical viruses have an inner channel located along their 
central axis which is not for the containment of the genome, which is instead 
sandwiched between successive layers of the helically-arrayed protein, but is rather 
necessitated by steric considerations. This inner channel also provides a potential 
location for the loading of cargo, although the lack of closure at either end needs to be 
addressed if the cargo is to remain contained. Both types of virus allow for the display 
of various types of useful signals or functional agents, such as peptides, proteins, 
fluorescent molecules, or chelating groups [59-63]. Generally, icosahedral viruses 
have a greater ratio of loadable volume to (inner or outer) surface area, while helical 






Icosahedral plant viruses: 
Red clover necrotic mosaic virus (RCNMV) is a structurally simple 
icosahedral virus in the Tombusviridae family, whose members “possess unusually 
stable and robust capsids” [64]. The capsid of RCNMV consists of 180 identical 
copies of the capsid protein subunit, which contains an inner cage consisting of RNA 
and protein, and each virion particle contains around 390 (±30) Ca2+ ion and roughly 
420 (±25) Mg2+ ions, or slightly more than four divalent cations per CP. CryoEM and 
three-dimensional (3D) image reconstruction were used to determine that RCNMV 
CP undergoes conformational changes upon depletion of its divalent cations, as 
would be expected upon relocation of the virion to the cytosol of a host cell. This 
conformational change causes the opening of pores through the capsid shell 
sufficiently large to allow the leakage of encapsulated ssRNA. This modulation of 
pore opening and closing by sequestration from and re-exposure to sufficiently high 
concentration of divalent cations was successfully exploited to enable the loading of 
imaging or therapeutic molecules, namely the fluorescent dyes rhodamine and 
luminarosine and the chemotherapeutic agent doxorubicin [65]. Notably, successful 
loading was only obtained with these positively or neutrally charged molecules and 
not with the negatively charged dye fluorescein, hypothesized to be due to 
interactions with the negatively charged RNA genome that is still present. 
Furthermore, the conjugation of N-cadherin-targeting peptide sequences to the 
surface of doxorubicin-loaded RCNMV particles caused increased their uptake by 





 Cowpea chlorotic mottle virus (CCMV), a member of Bromoviridae, similarly 
has a capsid of 180 identical CP subunits that bind to divalent cations. Upon 
sequestration of those divalent cations CCMV undergoes swelling and pore-opening, 
similarly to RCNMV but in a pH-dependent manner [67]. This response appears to be 
due to the electrostatic repulsion caused by negatively charged acidic residues at the 
Ca2+-binding site, and it only occurs at or above pH7, which is thought to be due to 
the abnormally elevated pKa of a single residue, Glu81, to around 7 due to its 
proximity to two other negatively charged amino acids, Asp153 and Glu111, against 
which it develops a repulsion upon protonation at higher pH in the absence of Ca2+ 
[68]. This swelling and poration is reversible and represents another possible strategy 
for loading and unloading of target molecules.  
Cowpea mosaic virus (CPMV) is another icosahedral virus under 
development as a functional nanoparticle. The virion is 30 nm in outer diameter and 
is composed of a “large” (41 kDa) and a “small” (23 kDa) capsid protein. CPMV was 
the first plant virus to be developed as a peptide-presentation system, made possible 
by the identification of sites within the coat proteins that would be allow surface 
exposure of inserted peptide sequences based on detailed three dimensional 
assembled protein structures [69-72]. The most common point of insertion is within a 
surface exposed loop of the small CP (the “S protein”) which results in the surface 
display of 60 copies of the inserted sequence per virion. It was determined that this 
method of display of short antigenic peptides increased their immunogenicity for the 





deposit silica or an iron-platinum alloy onto the surface of CPMV for the 
development of inorganic featured nanoparticles [74, 75]. 
Filamentous plant viruses: 
 One category of virus of particular interest is filamentous plant viruses. These 
viruses are notable for their simple structure, consisting of a single nucleic acid 
molecule encapsulated by multiple identical copies of a single coat protein subunit, 
and their characteristic elongated form providing a high aspect ratio and large surface 
area per unit volume. The characteristic properties of filamentous plant viruses, 
specifically their simple composition from a single, repeated CP subunit, present 
them as ideally suitable candidates to act as model systems to investigate the 
mechanisms that drive assembly of molecular subunits into higher order structures. 
Potato virus X (PVX): Carrette et al. replaced the CP gene for PVX with a 
gene for a fusion protein consisting of the CP fused at its C-terminus to Candida 
antarctica lipase B separated at the gene level by a sequence (“2A”) which is known 
to sometimes terminate protein translations [76]. This resulted in PVX particles 
arrayed with catalytically active enzyme that retained infectivity and were able to 
reproduce in vivo in the host. 
Steinmetz et al. focused on PVX as a model virus to explore the potential use 
of rod-shaped viruses for biomedical applications such as targeted drug delivery and 
imaging [63]. While the amino acid sequence of PVX’s 25 kDa CP is known (and 
known to contain 11 lysines, 10 aspartic acids, and 10 glutamic acids as potential 
bioconjugation targets), its crystal structure is not known, obscuring the precise 





However attempts to couple biotin to carboxylate residues were unsuccessful while 
amine-based labelling was successful, indicating the surface-accessibility of the 
lysine residues and the surface-inaccessability of the carboxylates. Bioconjugation 
methods including amine modification and “click” chemistry were established to 
functionalize PVX rods with biotin, fluorescent dyes (fluorescein, OregonGreen 488, 
and AlexaFluor 647), and PEGs of various molecular weights. The variously labelled 
hybrid nanoparticles were characterized to determine labelling efficiency. Labelling 
was determined to be highly efficient when bioconjugating a single fluorescent dye 
with 70-90% of CPs labelled, while doubly fluorescently labelled rods showed lower 
labelling efficiency (25-40%) but also used lower initial concentration conditions. 
PEG labelling showed lower efficiencies, with 20% and 40% of CPs labelled with 
PEG1000 and PEG2000, respectively. The higher labelling efficiency of the larger 
PEG, which may be surprising due to the expectation of steric effects inhibiting 
labelling, was hypothesized to be due to the increased hydrophilicity of the longer 
polymers assisting the coupling reaction. Cell interaction studies showed differential 
uptake of hybrid fluorescently labelled, PEGylated PVX particles by HeLa cells 
dependent on both which fluorescent dye was attached as well as the size of the 
conjugated PEG molecule, with PEG blocking uptake of OregonGreen 488-labelled 
particles but not of AlexaFluor 647-labelled particles and the larger PEG2000 labels 
even increasing uptake relative to PEG1000-labelled particles.  
Papaya mosaic virus (PapMV) is a member of Potexvirus that has been used 
to display a binding peptide (DPAPRPR) with specificity for the resting spores of the 





for the spores, allowing for the detection of these fungal spores, which had previously 
caused difficulty for detection using standard enzyme-linked immunosorbent assay 
(ELISA) due to unspecific cross reactions between fungal cell walls and the 
antibodies that these viral nanoparticles were designed to replace [77].  
 Tobacco mosaic virus as a model rod-shaped virus for 1.1.4.
nanomaterial synthesis 
 TMV is one of the most extensively studied and best characterized 
filamentous plant viruses. The TMV virion is a rigid but hollow tube-shaped rod, 18 
nm in diameter with a 4 nm diameter inner channel, consisting of roughly 2130 CP 
subunits arranged in a helix with a pitch of 23° with 16⅓ CPs per turn enveloping a 
single strand of plus sense RNA [78]. The length of the RNA genome limits the 
length of the assembled virion to roughly 300 nm. The CP has a molecular weight of 
17.5 kDa. Each CP subunit consists of a chain of 158 amino acids with four main 
alpha helices arranged radially in the assembled virion and connected by two inner 
loops and one outer loop with both the N- and C- terminus exposed on the outer 
surface of the assembled virion.  
 
 TMV enters a host cell passively through a wound to the cell wall. Upon 
reaching the cytoplasm, the relatively high pH and low calcium concentration initiates 
Figure 1-3: (A) TEM image of TMV, (B) models of full-length TMV rods, (C) magnified view of the 5’ end of a 






disassembly of the coat protein from the 5ʹ end of the genomic RNA due to the 
relative lack of guanines in the third position at this end of the RNA [79]. The 
exposed 5ʹ end of the RNA is then free to bind to host ribosomes, which strip the 
RNA of bound CP as it is translated in a process of co-translational disassembly. 
Newly formed TMV CP monomers begin to associate into dimers, trimers, and 
pentamers, which then assemble into flat protein disks. Upon interaction with newly 
formed genomic TMV RNA, the disks undergo a conformational change into a “lock-
washer” (short helical) configuration. As the RNA is situated in an RNA binding 
groove near the disk’s inner channel additional disks of coat protein are added to the 
growing rod’s 5ʹ end and the remainder of the RNA is drawn up through the inner 
channel until the full-length rod is formed [80].  
 TMV is a particularly attractive substrate for the creation of nanoscale 
materials. Detailed physical knowledge of TMV, including precise 3-D structural 
information [81, 82], virion assembly mechanism, and biochemical properties are 
understood in unique detail [65, 66, 83]. A full-length cDNA clone of the virus is 
available, allowing the design and creation of modified viruses. It is purifiable in 
large quantities from infected host plants, and its stability under a wide range of 
environmental conditions facilitates its incorporation into systems and devices [84]. 
While icosahedral viruses boast large interior chambers for cargo packaging and 
delivery, rod-shaped viruses like TMV have high-aspect-ratio geometries and large 
protein copy number per particle volume that make them ideal substrates and 
scaffolds [84]. The rod-shaped TMV has a high-aspect-ratio geometry (300 nm length 





an ideal substrate for the integration of tunable high-surface-area materials or densely 
arranged motif displays into functional devices. These properties have driven research 
into the use of TMV for the development of diverse applications, including anti-
reflective photochemical electrodes, super-hydrophobic surfaces, improved energy 
storage, and transducer surfaces for sensing applications [16, 17, 85-88].  
 Thesis Contributions 1.2.
 Development of self-assembling, nucleic-acid-free Tobacco 1.2.1.
mosaic virus-like particles 
 Despite the many advantages/potential toward the development of nanoscale 
functional material components conferred by/inherent in the use of filamentous 
viruses in general and TMV in particular, the use of “live” virus in this area of 
research has several drawbacks/disadvantages, including the need for plant growth 
facilities for virus production, the extended production time of plant-based infection 
and generation of virus, the risk of genetic recombination eliminating or altering 
intentional changes made to the virus, interference or resistance to 
structural/functional alterations to the virus due to the necessary incorporation of 
genomic RNA, and retention of infectivity of the viral product. These disadvantages 
are eliminated by the development of a virus-like particle based on the TMV CP, 
which self-assembled from protein components produced in bacteria and assembling 
without any incorporated genomic or non-genomic nucleic acids.  
This dissertation establishes the changes sufficient for the design and 





problems. This method uses structural data that identifies pairs of amino acids with 
similar charges that generate repulsive forces between adjacent viral capsid protein 
subunits, which discourage quaternary coassembly of the subunits into virus particles 
without the stabilizing incorporation of genomic RNA. These negatively charged 
amino acid residues are eliminated by alteration of the nucleic acid sequence that 
encodes the capsid protein. By also optimizing the gene for translation in bacteria and 
transforming that gene into an E. coli-based bacterial expression system, the resulting 
protein product reliably generates VLP which can be more rapidly modified and 
produced than virus, without incorporated RNA, and which retains the robust range of 
stability of the virus upon which it is based. Furthermore, modifications made to the 
CP to functionalize the resulting nanoparticle are retained or, in the case of larger 
peptide fusion products encoded in the CP gene, enhanced by means of eliminating 
loss of the modification through genetic recombination. 
Work toward the accomplishment of this aim was contributed by Lindsay 
Naves and Xiao Wang. This work was published in Biomacromolecules as 
“Carboxylate-Directed In Vivo Assembly of Virus-Like Nanorods and Tubes for the 
Display of Functional Peptides and Residues” (2013) 
 Development of VLP-forming capsid protein variants with 1.2.2.
unique environmentally responsive disassembly and 
reassembly behavior 
 One advantageous property of biologically based nanomaterials is the 
tunability of the self-directed bottom-up assembly process. Biological systems are 





requires them to have control over the disassembly of nanostructural features in 
addition to their assembly and to direct these behaviors in response to environmental 
stimuli. This can be accomplished by the direct action of an environmental factor on 
key elements of the nanostructure that underlie the assembly mechanism. This type of 
control over assembly and disassembly of VLPs would greatly extend the usefulness 
of VLP-based nanomaterials by allowing for a mechanism for restoring the 
components of the nanomaterial to a pre-assembled state for reorganization of the 
system or reuse in another system as well as generating additional potential 
applications by allowing for environmentally sensitive structural and behavioral 
responses of the system. In the case of TMV, disassembly is triggered by 
environmental changes encountered upon entry to a host cell. A change in hydronium 
ion concentration (pH) and other dissolved ion (such as Ca2+) concentrations directly 
and indirectly alter the electrostatic charge-based interactions between adjacent CP 
monomers. By modifying the residues responsible for these interactions in a 
deliberate way, the character of the aggregate intersubunit interactions is also 
modified in ways that shift the effect of pH and solution salinity on particle assembly 
stability. These targeted modifications generate TMV CP variants with unique surface 
charge profiles and dynamic responses to changes in pH and/or concentration of 
dissolved ions. 
This work and the following work were presented at the 15th Annual 
Conference on Foundations in Nanoscience: Self-Assembled Architectures and 





 Multifunctional chimeric VLP-virus nanorods with 1.2.3.
longitudinally differentiable regions using controlled self-
assembly of protein components 
 TMV and VLP nanorods are versatile components for functionalizing surfaces 
and fluids, but each nanorod is composed of identical copies of a single CP or a 
homogeneous mixture of CPs when combined with leaky stop codon readthrough, so 
any modification to the underlying CP structure is present along the entire length of 
the resulting nanorod, generating relatively simple nanostructures that are 
functionally undifferentiated along their axial dimension. The ability to vary the 
properties of these nanorods along the axial dimension would expand their range of 
potential applications and power of use by introducing an additional dimension of 
organizational complexity. This feature would allow for the combination of multiple 
additional functional capabilities into each nanorod, conferring added functionalities 
such as capping of VLP for selective cargo molecule containment and 
environmentally controlled release, improved combination of target sensing and 
signal transduction functions along the spatial optimal portions of the nanorod, and 
spatially segmented tethering of enzymes for control of enzyme cascades for energy 
harvesting or chemical processing.  
 This research combines the unique electrostatic surface charge profiles at the 
ends of various VLP rods produced from engineered TMV CP with the unique 
assembly behaviors of those rods to develop methods for generating scalable batch 
production of complex rod-shaped nanoparticles composed of discrete, well ordered 





Portions of this work were presented at Gordon Research Conference for 
Virology in Ventura, California (2015) and the American Society for Virology 
Conference in Blacksburg, VA (2016) 
 Literature Review 1.3.
 The following section will review some of the most characteristic work in the 
fields of research most relevant to the project presented in this dissertation. The 
section will begin by addressing viruses generally with a focus on plant viruses in 
particular and Tobacco mosaic virus specifically. The remainder of this section will 
review research and principles covering the structure and assembly of TMV, and the 
modification made to TMV and other viruses to create novel nanofeatured materials 
through altered assembly, patterning, and functionalization. 
 Modifications affecting assembly 1.3.1.
An understanding of the processes and conditions underlying TMV self-
assembly has allowed for targeted changes to alter the particle’s physical properties. 
These include changes to the CP, to the RNA scaffold around which the CP 
assembles, or to solution conditions driving assembly and disassembly. The resulting 
changes range from the shapes and dimensions of the particles produced (from short 
disks to micrometer-length wires), to their shape (from branched rods to spheres) to 
the distribution of functional groups along the length of the rod. 
One general method for structural TMV modification exploits the ability of 
disassembled TMV CP to reassemble in vitro in the presence of single-stranded RNA 
containing an origin of assembly sequence (OAS) motif [89]. CP with modifications 





assembly in vitro using a mixture of modified and unmodified CP. This method was 
used to incorporate various amounts of CP with surface-exposed, C-terminal 
hexahistidine (His6) tags which had resisted virion formation in vivo [90]. Similarly, 
this method was used to coassemble bacteria-expressed CP, which lacks N-terminal 
acetylation and will not assemble with RNA in vitro, and plant-expressed CP, which 
is acetylated and does reassemble, into stable virions and in specifiable proportions 
[91]. Furthermore, various CPs with distinct functionalities (bioconjugation sites, 
peptide tags, etc.) can be organized in discrete sections along the length of the particle 
by sequential introduction of the different CP variants to the RNA scaffold in vitro 
due to the assembly process which progressively adds CP to the RNA scaffold from 
the OAS near the 3ʹ end towards the 5ʹ end [92]. Because the length of the TMV rod 
is primarily constrained by the length of the genomic RNA scaffold it contains, 
changing the length of that RNA scaffold can be used to control the length of the 
resulting nanoparticles either in vitro [93] or in planta [94]. The use of branched 
nucleic acid scaffolds has even been used to introduce kinked or branched structures 
instead of linear rods, creating “nanoboomerangs” and “multipods” [95]. 
Of particular significance to the research presented in this document, a method 
of ordering the longitudinal composition of TMV nanorods into discrete sections was 
reported by Geiger et al. This was accomplished by disassembling purified modified 
TMV and using the directional assembly of the CP onto the genomic RNA [92]. In 
these experiments, TMV modified by the addition of either a cysteine residue to the 
N-terminus of the CP ORF (S3C) or by the addition of lysine to the C-terminus 





constituent CP, which was then subsequently 
incubated with genomic wild-type TMV RNA or a 
linearized infectious plasmid containing the 
genomic RNA in a serial manner to allow assembly 
of first one and then the other modified CP onto the 
RNA. This resulted in hybrid TMV particles with 
typical lengths dictated by the RNA core material 
but with different functionalities present along the 
longitudinal dimension of the rod, as determined by 
the modifications made to the component CP and 
verified by TEM of chemically conjugated enzymes. One drawback of this method is 
the bidirectional nature of TMV CP assembly onto the RNA scaffold. While the 
addition of CP onto the 5ʹ end of the forming rod occurs more quickly and easily than 
addition to the 3ʹ end, combined with the location of the OAs nearer to the 3ʹ end of 
the RNA genome, results in the extension of the nascent rod primarily in the 3ʹ to 5ʹ 
direction, the slower addition of CP to the 3ʹ end results in rods which are not strictly 
ordered in CP composition (Figure  1-6). 
Plant viruses depend on the quaternary assembly of structural capsid proteins 
around the genome to protect it from environmental degradation. However the 
genome needs to be made available to host ribosomes upon entry into the host cell’s 
intracellular environment to initiate the infection and reproduction process. This 
bimodal status of either stabilized or destabilized macromolecular assembly 
dependent on environmental conditions has been shown to be controlled, at least in 
Figure 1-4: Sequential reassembly of two 
different TMV CP variants onto the RNA 
scaffold to produce nanorods with 
distinctly addressable regions. Reprinted 






part, by clusters of carboxylate-containing residues which interact at intersubunit 
interfaces [96, 97]. These negatively charged residues generate electrostatic repulsion 
between adjacent capsid subunits in the cytoplasm of a host plant cell, but this 
repulsion can be offset by the presence of calcium ions or hydronium ions, leading to 
a stabilized particle in the extracellular environment. 
 One general method to alter particle assembly is primarily driven by 
engineered changes to the CP gene to manipulate the normal assembly behavior. By 
altering the amino acid residues located at the interface of adjacent CP monomers or 
at the protein-RNA interface, the dynamics of particle assembly can be altered. TMV 
mutants with enhanced stability of the macromolecular capsid protein assembly and 
inhibited/reduced disassembly proclivities were generated by systematically 
substituting out the carboxylate-containing residues aspartic acid (D) and glutamic 
acid (E) implicated in intersubunit interactions with neutrally-charged but similarly 
sized carboximide-containing residues asparagine (Q) and glutamine (N), respectively 
[96-98]. The two clusters that had been implicated in repulsive intersubunit 
interactions were (1) E50 and D77, which interact between capsid subunit situated 
adjacent to one another along the virus rod’s axial dimension, and (2) E106 which 
interacts with the E95-E97-D109 amino acid triad in a lateral direction. Mutants with 
the E50Q, E106Q and combinations of E95Q/E97Q/D109N mutations showed 
reduced in vivo infectivity and in vitro cotranslational disassembly indicating 
stabilization of the capsid protein macroassembly. Mutants were also characterized as 
having lower OD260/280 ratios, indicating macromolecular assembly of capsid protein 





including rods both shorter and longer than individual wild-type TMV particles. The 
E50Q mutation alone has been used more generally to promote particle assembly and 
stability for longer particle lengths [99] and when incorporating destabilizing CP 
alterations [100].  
Another tactic introduces covalent bonding between adjacent CP subunits to 
confer stability to helical protein assemblies. One method introduced a cysteine to the 
flexible loop composing the surface of the virion inner channel at the low-radius 
portion of the assembled particle [101]. This cysteine (T103C) could interact with 
either of the identically positioned cysteines located on the neighboring CP subunits 
situated laterally to it. The resultant disulfide bonds stabilized the formation of helical 
rods under conditions which limit wild-type CP assembly to the formation of disks. 
Additional work introducing cysteines to the N-terminus (positions 1 and 3, located at 
the high-radius, outer surface of 
assembled disks or rods) in 
addition to the aforementioned 
inner loop cysteine T103C further 
allowed for the organization of 
disks or rods into various regular 
arrays or bundles depending on 
solution pH and ionic conditions 
[102].  
 Other mechanisms to control TMV nanoparticle assembly and morphology 
depend on manipulating interactions between adjacent CP subunits. One significant 
Figure 1-5: Introduction of a cysteine near the inner channel 
surface to create stabilizing, covalent disulfide bonds between 
adjacent CP. Reprinted with permission from [101]. Copyright 





and well-studied interaction is an electrostatic repulsion between carboxylate-
containing residues. Because the negative charges of those residues are pH-
dependent, and because their interaction is influenced by the absence or presence of 
soluble ions, solution pH and ionic strength conditions can be used to promote 
assembly or disassembly. This can be used to generate particles with alternative 
shapes and aspect ratios. TMV CP, either purified and isolated from its genomic RNA 
or expressed and purified from bacteria or yeast, forms a mixture of short rods, disks 
and monomers at neutral pH and low ionic strength. Increasing the ionic strength of 
the solution (from 100 to 400 mM acetate) promotes the assembly of a four layer disk 
consisting of two bilayer disks facing opposite directions arranged in a “head-to-
head” orientation [103, 104]. Alternatively, lowering the solution pH below ~5.5 
induces CP to assemble into rods by protonating and neutralizing the carboxylate 
groups, eliminating their mutual repulsion [96, 105], allowing the hydrophobic 
interactions between layers of CP to drive assembly. Because these carboxylate 
groups are also exposed at the ends of the virus rod, their interaction inhibits the 
“head-to-tail” assembly of two TMV rods. Lowering the solution pH promotes the 
coassembly of TMV rods into long nanofibers whose structure can be stabilized and 
fixed by the surface deposition and polymerization of an appropriate molecule. TMV 
retains a negative surface charge above its isoelectric point (around pH 3.3 [106]), so 
positively charged polymer precursors accumulates on the long TMV fibers that form 
when the pH is near 5. Soluble, micrometer-scale, polymer-coated TMV nanofibers 
that remain stable at neutral pH have been achieved by surface deposition and 





Polymerization of the aniline on the surface of TMV facilitated the head-to-
tail attachment even at neutral pH, although the morphology of the resulting hybrid 
material was controlled by the pH of the reaction, with short bundles produced at very 
low pH(=2.5), long bundles produced at pH5, and long disperse nanofibers at pH6.5 
[108, 109]. Although this method achieves end-to-end assembly of TMV, it does so 
indiscriminately with respect to head-to-tail order, and the resulting nanofiber has a 
continuous polymer coating, which could interfere with previous functionalizations of 
the TMV particles themselves. 
 Patterning and positioning TMV on surfaces and integrating 1.3.2.
TMV into devices 
 Attachment or deposition of virus onto surfaces is a critical prerequisite for 
the implementation of the virus’s novel capabilities as components of functional 
devices. Selective or directed deposition of the virus onto specific surfaces, and 
specifically in designated patterns, can also enhance the virus’s effectiveness in 
certain applications. Toward this end, several methods have been developed that can 
quickly pattern TMV over large surfaces for subsequent use. 
 One simple method of aligning virus rods on a surface utilizes fluid and air 
flow, wherein an aqueous solution of TMV is removed from a surface either by blow-
drying the droplet or by capillary forces using filter paper [111]. TMV left behind are 
oriented in the direction of fluid flow due to shear forces within the fluid at the 
surface boundary. Surfaces with strong TMV interactions, such as highly polar 





interactions, such as carbon, benefit from the lateral suction of the liquid. These 
methods represent a relatively simple means of generating aligned virus on a surface. 
 Another convective method of depositing TMV onto a surface was developed 
that enables deposition in a variety of particle orientations and thicknesses [112]. In 
this method, a liquid suspension of TMV is dragged over the surface substrate by the 
movement of a parallel glass slide, with an assembly front at the leading edge of the 
droplet and a drying front at the trailing edge. The roughness of the resulting TMV 
deposition depends on the surface energy of the substrate, with increasing water 
contact angle correlating with increasing surface roughness. Variation of virus 
concentration and assembly speed can be used to controllably vary the particle 
orientation, packing density, and thickness of the resulting viral deposition, with four 
observed deposition regimes: (1) incomplete monolayer with parallel orientation, (2) 
monolayer with parallel orientation, (3) multilayer with disordered orientation, and 
(4) multilayer with antiparallel orientation.  
 An alternative method of depositing TMV onto surfaces using a genetic 
modification of the virus creates a more robust attachment between the rods and the 
surface while also generating a vertical orientation of the virus relative to the surface. 
This genetically modified form of the virus, TMV-1cys, contains a single cysteine 
residue inserted within the N-terminal domain of the CP open reading frame. As part 
of the CP N-terminal region, the cysteine is located at the outer surface of the 
assembled virus rod, where it can form bonds with various surfaces including gold, 
stainless steel, Teflon® (PTFE), SU-8, Si, and SiN [56, 85, 88, 113, 114] through the 





N-terminal region is partially shielded by the C-terminal arm. This partial obscuring 
of the cysteine likely inhibits the direct contact of the cysteine sidechain’s thiol group 
with the surface except at the virus’s 3ʹ end, where the thiol has greatest exposure. 
The result is the spontaneous vertical attachment of TMV-1cys from its 3ʹ end to 
these materials upon incubation with an aqueous solution of the virus, radically 
increasing the theoretical ratio of utilizable and exposed virus surface area per 
substrate surface area compared to previous method of attachment with parallel 
surface--virus orientation. Due to the selectivity with respect to surface material 
composition for attachment of TMV-1cys, patterned deposition of a TMV-1cys-
binding material onto a surface can direct virus-deposition patterning. TMV-1cys has 
also been deposited onto silicon and SU-8 three-dimensional microstructures, further 
increasing the functional virus surface area per footprint surface area beyond that 
afforded by the perpendicularly oriented surface attachment of TMV-1cys. 
Standard microfabrication methods can be used to pattern TMV-1cys on a 
surface after virus deposition. Lift-off is a technique where a patterned photoresist 
mask defines areas where a subsequent layer, such as metal, will be removed at the 
end of the process. This process has been demonstrated to be compatible with TMV-
1cys, both uncoated and metal-coated [115]. For uncoated TMV-1cys, either acetone 
and ultrasonication or a standard photoresist developer diluted with sodium phosphate 
buffer to reduce the pH to one within TMV’s range of stability was used to dissolve 
the photoresist mask, which had already been flood exposed prior to the virus 
deposition process. This process resulted in very well-defined patterning of the virus, 





 A final approach for the surface attachment and patterning of TMV utilizes 
DNA hybridization methods [116]. This approach exploits the normal method of 
TMV virion assembly whereby TMV CP, in monomer, oligomer, and assembled disk 
forms, assembles itself around the genomic RNA. Silicon wafers were prepared using 
polymer blend lithography allowing exposed silicon regions to be functionalized by 
the attachment of linker DNA that binds via nucleic base pairing to strands of TMV 
genomic RNA. Incubation of the prepared surface with a solution of TMV CP 
generates assembly of surface-attached virions by assembly of CP onto the surface-
attached RNA. The virus/VLPs are present only in areas initially treated to bind the 
DNA linkers, but despite the physical point of attachment of the rods to the surface, 
the rods were observed to lie flat on the silicon surface in randomly distributed 
orientations. 
 TMV Surface Functionalization 1.3.3.
 TMV, as a nanoparticle with a defined and repetitive architecture, can act 
within systems as a nanoscale scaffold for the anchoring, arrangement, and display of 
biochemical motifs. For some applications, the native functional groups displayed on 
the surface of the wild-type virus are sufficient to achieve the desired ends. However 
one important capability afforded by virus particles is the customizability of their 
surface. A variety of genetic and post-translational modifications have been 
developed to enable TMV to function as a general purpose scaffold for the display of 
an enormous variety of molecules and functional groups.  
A common theme of research in this area is the recruitment of TMV as a 





tissues for uptake and delivery of either therapeutic, prophylactic or 
imaging/reporting molecules (or of both in the case of theranostic technology). For 
targeted drug delivery, the attachment of (chemo)therapeutic agents to the TMV inner 
or outer surface can be combined with the display of moieties such as carbohydrates 
or proteins that target uptake by a tumor or other tissue together with other molecules, 
such as PEG, to escape detection by the immune system or clearance by the liver. 
Alternatively the “highly ordered, repetitive, quasicrystalline display” of antigen 
epitopes when displayed on the TMV surface provides an enhanced immunogenicity 
for vaccine applications or the production of antibodies when detection by the 
immune system is intended [117]. The primary modifications explored in this review 
are summarized in Table 1.  
 The amino acid side chains exposed on the surface of virus and virus-
derived particles provide a variety of reactive sites for the chemical conjugation of 
desired molecules and moieties, whether these amino acids are naturally present or 
artificially introduced. Specifically, two TMV variants, altered by the addition of a 
single cysteine (TMV-1cys) or lysine (TMV-1lys) residue to the N-terminal region of 
the CP, have proven to be reliable scaffold for the conjugation of small fluorescent 
molecules. TMV-1cys can be decorated with molecules containing a maleimide 
functional group through the well-established thiol-maleimide reaction generating a 
covalent bond, while TMV-1lys can be similarly decorated via a reaction between the 
amide of lysine and an NHS-ester functional group. These two variants, TMV-1cys 
and TMV-1lys, were fluorescently labelled with maleimide-fluorescein and NHS-
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indicate that each TMV-1cys and TMV-1lys virion displayed ~1850 and ~1400 
fluorescein molecules, respectively, corresponding to a fluorescein labelling of ~85% 
and ~65% respectively of each of the ~2130 CP subunits comprising each virion. The 
presence of a fraction of CP in each sample without bound fluorescein was confirmed 
with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry 
(MALDI-TOF MS). The reduced fraction of fluorescently labelled (fluorescein-
bound) TMV-1lys CP subunits was hypothesized to the due to steric hindrance due to 
the larger size of the NHS-ester group relative to maleimide. 
 Similarly, phenol groups naturally present in the sidechains of surface 
exposed tyrosine residues in wild-type TMV have be shown to be functionalizable by 
binding oligo-aniline (OANI) motifs [131]. This involved a three-step bioconjugation 
protocol that attached the terminal alkynes of OANI to the phenol groups on the TMV 
rod surface to produce OANI-labelled TMV (TMV:OANI). To prevent aggregation 
and bundling of TMV:OANI, dimethyl sulfoxide can be added to the nanoparticle 
solution to inhibit reaction between OANI units, similar to the use of DTT to prevent 
crosslinking of TMV-1cys by the creation of disulfide (cystine) bonds. 
 The functional groups present and solvent-exposed on the surface of 
unmodified TMV include a tyrosine residue (T139), whose phenol group is exposed 
on the outer surface, and two glutamic acid residues (E97 and E106), whose 
carboxylate groups are exposed on the surface of the inner channel. Bioconjugation to 
the exterior tyrosine’s phenol can occur by azo-coupling through the use of 
diazonium salts, while the inner channel glutamic acid residues can be activated by 1-





target molecules via an amide bond [123]. Further strategies to increase the range of 
products and efficiency of bioconjugation to the external tyrosine include the azo-
coupling of an alkyne group, allowing the Cu(I)-catalyzed azide-alkyne cycloaddition 
reaction (CuAAC), a type of “click” chemistry [132], and the further addition of β-
cyclodextrin by CuAAC, allowing the strong but noncovalent attachment of 
adamantyl-coupled molecules [122].  
 A lysine inserted at the CP N-terminus similarly allowed for bioconjugation to 
the outer surface of TMV through a reaction between the lysine’s amide group Dual 
attachment by independent targeting of the outer and inner surfaces of the TMV 
allows for separate functionalization of these two surfaces. Given the potential of 
TMV for use for theranostic, targeted drug delivery, or imaging purposes, 
bioconjugated elements that have been selectively bound to TMV include fluorescent 
dyes Surface-exposed functional groups provide selective sites for chemical 
bioconjugation, broadening allowable modifications while avoiding assembly 
disruptions that sometimes result from genetic modifications. Naturally occurring 
bioconjugation sites include an outer-surface-exposed tyrosine (T139) and two inner-
channel-accessible glutamic acids (E97 and E106). Bioconjugation to the tyrosine’s 
phenol can occur by azo-coupling using diazonium salts, while the inner-channel 
glutamic acids are activated by 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
(EDC) and coupled to amine-linked targets via an amide bond [123]. The azo-
coupling of an alkyne group to the exterior tyrosine allows the use of Cu(I)-catalyzed 





simplifying further modifications. The addition of β-cyclodextrin by CuAAC, allows 
the noncovalent attachment of adamantyl-coupled molecules [122].  
 Independent targeting of TMV’s tyrosines and glutamates allows heterologous 
functionalization of their distinct surfaces. Given TMV’s potential drug delivery and 
imaging applications, bioconjugated molecules include fluorescent dyes [120, 122], 
paramagnetic contrast agents for MRI [9], poly(ethylene glycol) to tune circulatory 
clearance rates [122, 123], carbohydrates [121], folic acid [122] and peptides (cRGD) 
[91] to direct receptor-mediated endocytosis, and pharmaceutical agents including 
doxorubicin [91, 122] and cisplatin [121]. Additionally it was shown that the negative 
charges provided by the glutamates (E97 and E106) exposed along the inner channel 
of the virus are alone sufficient for the non-covalent loading and retention of ~800 
copies of a triply cationic porphyrin-based photosensitizer per virion [119] or ~2000 
copies of the doubly cationic DNA-binding anticancer drug candidate 
phenanthriplatin per virion (approximately one molecule per CP) with subsequent 
release of phenantriplatin shown in acidic environments [8].  
 To expand the range of methods for functionalizing TMV and the possible 
targets of binding, several modifications to the TMV CP to introduce new functional 
groups at the virus surface have been made. A genetic insertion encoding one or more 
cysteine residues near the N-terminus of the CP provides several advantages. The 
surface-exposed thiol groups allow for improved metal deposition on the virus 
surface [114] including confluent Ni, Co, Pt, Pd coatings of tunable thickness. The 
orientation of the cysteine directs the perpendicular attachment of TMV rods to 





114]. The cysteine also enables the use of well-established reactions between thiol 
and maleimide as an alternative method of bioconjugation to the external surface of 
TMV. This method has been used to attach fluorescent dyes (Texas Red [133] and 
Atto 488 [92]) or biotinylated PEG, which allowed the subsequent attachment of 
streptavidin-labeled enzymes including horseradish peroxidase [92] and glucose 
oxidase [126] with an efficiency of approximately one thousand enzyme molecules 
per TMV rod, indicating that roughly half of all CP subunits bound to an enzyme 
molecule [126].  
 A lysine inserted at the CP N-terminus similarly allowed for bioconjugation to 
the outer surface of TMV through a reaction between the lysine’s amide with an N-
hydroxysuccinimide (NHS)-ester-labeled target. Smith et al. generated a library of 
TMV with three random amino acids and a lysine at the N-terminus and isolated an 
infectious and soluble clone containing the sequence ADFK [124]. Biotinylation of 
the lysine residue with NHS-PEO4-biotin allowed decoration of the virus with 
streptavidin-linked whole proteins (GFP) and peptides (a fragment of Canine oral 
papillomavirus L2 protein) with a loading efficiency of 26% to function as protein 
antigen display scaffolds for vaccine applications [124]. Demir et al. had previously 
added a lysine to the C-terminus of the CP (T158K) with no other modifications for 
particle solubility improvement, but showed the ability to biotinylate the rods with 
NHS-biotin and subsequent binding of avidin [134]. Altintoprak et al. conjugated 
cysteine containing polypeptides between nine and twenty-one amino acids in length 
to the C-terminal lysine using bifunctional PEG linking maleimide and NHS groups 





 Another strategy to functionalize viral surfaces is to alter or extend the CP 
open reading frame (ORF) by genetic modification so that the introduced peptide 
sequence is located at the desired surface of the assembled viral particle. The C-
terminus of the CP is an ideal site for additional peptide sequences, if it is located on 
the relevant surface of the assembled particle, due to a decreased likelihood of the 
added peptide sequence interfering with cotranslational protein folding. In general, 
short peptide sequences, less than ~25 amino acids in length, have the best results in 
being incorporated into virus/VLP/PVN structure by minimizing interference with CP 
folding and NP assembly [135]. However, even short peptide sequences can inhibit or 
even prevent virion assembly in a manner highly dependent on the particular protein 
sequence for reasons that may be either obvious (such as a large number of 
hydrophobic residues) or not easily predicted [136].  
 One strategy to functionalize virus particles is to genetically alter or extend 
the coat protein (CP) open reading frame (ORF) by genetic modification to introduce 
a peptide sequence at the desired surface of the assembled viral particle. The well-
established crystal structure of TMV CP in the assembled state [78] indicates that the 
high radius region on the outer surface of the TMV virion includes the CP N-
terminus, C-terminus, and a surface exposed loop containing residues 63 to 66 [114, 
124, 137]. Insertions of sequences at each of these three sites have produced 
infectious virus that assemble into stable virions. The C-terminus of the CP has been 
the preferred site for additional peptide sequences due to a decreased likelihood of the 
added peptide sequence interfering with cotranslational protein folding. In general, 





folding and virion assembly [136]. The ability to display short (<~25 a.a. residues in 
length) peptide sequences enables virus-based particles to display peptide tags that 
can act as targets for other molecules such as antibodies or that can selective target 
molecules on their own, effectively transforming the virus-based particle into a 
multivalent biosensor. However, even short peptide sequences can prevent virion 
assembly in a manner highly dependent on the particular protein sequence for reasons 
that may be either obvious (such as a large number of hydrophobic residues) or not 
easily predicted [135].  
 Larger peptides, including proteins, as well as some smaller peptides that 
appear to inhibit virion assembly can also be added to the CP through extension of the 
CP ORF and assembled particles can be obtained provided that the particles are 
allowed to assemble from a mixture of augmented and unaugmented (“wild-type”) 
CP subunits. This mixture can result from the coexpression of wild-type CP either 
independently or through the use of a “leaky” stop codon. Leaky stop codons have 
some probability of not terminating translation but instead of being read-through and 
producing a protein of extended length [138]. Virus-based particles so produced have 
the added peptide or protein fused to only some subset of their CP subunits, with a 
random “mosaic” distribution, and so compromise the number of peptides displayed 
per particle in order to allow particle assembly. Peptide additions as large as the 
fluorescent proteins GFP and mCherry have been added to the CP of PVX and 
produced assembled virions using these techniques [138, 139]. However in some 
cases even large peptide additions have been added to a virus CP ORF and produced 





amino acid segment of protein A which was fused to the TMCP ORF and produced 
assembled virions that demonstrated binding of antibodies along the entire length. 
 A common use of this peptide display capability has been the multivalent 
display of epitopes for the detection of antibodies or for the production of an immune 
response as a vaccine component. For instance, TMV CP with a C-terminal FLAG 
tag (DYKDDDDK) was used to generate virus-like particles (VLPs) that were 
deposited on an optical disk resonator to demonstrate a highly sensitive 
immunosensor targeting anti-FLAG antibodies [6].  
 TMV peptide display can also use the specificity and high affinity with which 
short polypeptides can selectively target and bind molecules. Such peptide sequences 
can be isolated and identified from phage display libraries of short peptides used to 
screen for bond strength to the target analyte [140-142]. One such binding peptide 
with specificity to 2,4,6-trinitrotoluene (TNT) was expressed as a TMV CP fusion to 
generate virus-like particles. These particles were used in solution, where their 
binding to dissolved TNT altered the diffusion rate of TNT to an electrode, changing 
the peak corresponding to the oxidative reduction of TNT in response to square wave 
voltammetry for the purposes of TNT detection [127]. 
 Other examples include expression of the integrin receptor target amino acid 
sequence arginine-glycine-aspartic acid (RGD) on the TMV surface. This allowed 
TMV to serve as mimics of extracellular matrix proteins with unique consistency and 
structural patterning to serve as a substrate for the culture of stem cells [129, 130]. 
 The ability to express short peptide sequences as contiguous parts of the TMV 





area nanoscale peptide display scaffold with no further modifications. However these 
genetic insertions can produce destabilizing effects. Depending on the peptide, 
purifiable virus yield may be low, or virus rods may fail to assemble completely form 
entirely for reasons not easily predicted [135]. Given the time and effort required to 
modify and clone a genetic TMV variant prior to discovering whether sufficient virus 
yield will be produced,, many groups opt instead for post-translational bioconjugation 
of functional groups, including peptides, to assembled virus.  
 Summary 1.4.
 Contribution of Research Project 1.4.1.
 This project used TMV VLPs as a model system to investigate controlled 
macromolecular assembly of simple protein components into more complex, higher 
order multimacromolecular biological nanostructures capable of diverse functions in 
integrated devices. This was accomplished through a multiphase project comprising 
(1) the development of TMV VLPs by the bacterial expression and isolation of 
modified TMV CP capable of assembling in the absence of the RNA genome, (2) 
the further development and characterization of VLP-forming modified TMV CP 
with unique environmentally responsive assembly behavior, and (3) the 
establishment of methods to use these modified CP variants to create in the form of 
end-to-end attachment of TMV VLPs to create chimerical multirods by the 
controlled, directed macromolecular assembly of heterogeneous VLP 
components of differentiable function. This project will function as model for 
further development of functional micromolecules with applications in targeted drug 





applications in a single platform. Such research is expected to enable the development 
of new, low cost, environmentally responsive materials and surfaces with improved 
sensing, storage and release capabilities for threat and disease detection, information 
processing, and therapeutic application. 
 Structure of Dissertation 1.4.2.
 Chapter 1 has attempted to establish the basis for this research project by 
explaining its motivation and reviewing the literature establishing the state of the 
field. The following chapters will describe the major achievements that have been 
made in pursuit of its goals. Chapter 2 will describe the initial strategies that allowed 
for the first production of functional virus-like particles from bacterially expressed 
Tobacco mosaic virus capsid protein. Chapter 3 will introduce the further strategies 
that lead to the creation of multiple alternative TMV capsid protein variants with 
unique and divergent behaviors with respect to macromolecular assembly and will 
describe the use of these modified forms of TMV CP to generate particulate 
nanomaterials with an additional layer of architectural complexity. Chapter 4 will 









Chapter 2: Assembly of Virus-Like Particles from 
Modified Tobacco mosaic virus Capsid Protein1 
 Abstract 2.1.
 Uniform dimensions and genetic tractability make filamentous viruses 
attractive templates for the display of functional groups used in materials science, 
sensor applications and vaccine development. However, active virus replication and 
recombination often limit the usefulness of these viruses for such applications. To 
circumvent these limitations genetic modifications of selected negatively charged 
intersubunit carboxylate residues within the coat protein of Tobacco mosaic virus 
(TMV) were neutralized so as to stabilize the assembly of rod-shaped virus-like 
particles (VLPs) within bacterial expression systems. Here we show that TMV-VLP 
nanorods are easily purified, stable and can be programmed in a variety of 
configurations to display functional peptides for antibody and small molecule 
binding.  
                                                 
 
1 This chapter comprises the text of the published article "Carboxylate-Directed In Vivo Assembly of 
Virus-like Nanorods and Tubes for the Display of Functional Peptides and Residues," written by A. D. 
Brown, L. Naves, X. Wang, R. Ghodssi, and J. N. Culver, appearing in Biomacromolecules, vol. 14, 
pp. 3123-3129, Sep 2013. The manuscript was written through contributions of all authors. All authors 
have given approval to the final version of the manuscript. Authors A. D. Brown and L. Naves 








Virus particles are remarkable examples of biological evolution. They consist 
of individual components that encode the ability to self-assemble into uniform nano-
scale shapes. These traits have made viruses attractive templates for use in 
nanotechnology applications. Furthermore, the protein and genetic components that 
make up these particles display a unique level of malleability that enables both 
genetic and chemical modifications for the addition of novel functionalities that 
include vaccine epitopes, moieties for the mineralization of inorganics, and genetics 
for the patterning of virus particles [143-146]. Yet despite these traits the application 
of virus particles is often limited by problems associated with viral replication and 
recombination that result in the loss of the desired functionalities. In addition, size 
constraints dictated by the need to include replication competent virus genomes also 
reduce the potential application of these particles. However, many of these limitations 
can be circumvented by the use of virus-like particles (VLP) derived from the 
assembly of virus structural proteins in the absence of the virus genome [147-149]. 
Yet a number of virus coat proteins, filamentous viruses in particular, are not 
amenable to particle assembly in the absence of nucleic acid. Here we describe an in 
vivo VLP assembly system for the filamentous Tobacco mosaic virus (TMV) and its 
application for the display of functional binding residues and peptides.  
TMV has served as a model virus for use in a variety of applications [150]. 
TMV forms a nanotube structure 300 nm in length and 18 nm in diameter with a 4 nm 
diameter hollow inner channel. Each particle is assembled from ~2130 identical 17.5 





RNA [151]. TMV particles are stable up to 60 °C and at pH range of 2-10 [152] and 
are amenable to genetic modifications for the addition of novel functionalities that 
include inorganic binding and vaccine epitope display [150, 153, 154]. Combined, 
these traits make the virus a durable biological template. However, the use of 
infectious TMV imparts limitations associated with virus recombination and 
replication [154]. In addition, in planta production of virus particles requires 
specialized plant growth conditions and produces an infectious particle. These 
limitations often result in the loss of genetically added sequences via recombination 
or the inability to generate sufficient quantities of virus particles due to interference in 
the virus life cycle by the added sequence or peptide [155]. 
Previous studies have demonstrated that the TMV coat protein can be 
expressed and purified from Escherichia coli [156-158]. However, at neutral pH 
purified TMV coat proteins are only capable of assembling into lower order disk-
shaped aggregates. Assembly of these aggregates into characteristic rod-shaped 
particles requires the co-expression of RNA containing the virus origin of assembly, 
leading to the production of VLPs containing nucleic acid [159]. Alternatively, 
exposure of purified coat protein to pH 5 buffer conditions is also known to induce 
the formation of rod-shaped particles [160]. Both of these approaches entail 
drawbacks that can limit the usefulness of the TMV coat protein generated VLPs. For 
example, recruitment to the bacterial polyribosomes can significantly disrupt the 
production of RNA assembled VLPs [159]. Furthermore, the presence of nucleic acid 
within the rod may be undesirable for some applications. Assembly through post-





for many biological and chemical functions lead to the disassembly of these VLPs, 
thus limiting their use. New methods that permit the self-assembly of the TMV coat 
protein under biological relevant conditions are needed. 
Stability of the TMV particle is modulated by repulsive carboxylate groups 
located on opposite sides of subunit-to-subunit interfaces [151, 161]. These 
negatively charged repulsive interactions are stabilized by protons and Ca++ ions that 
function as a stability switch. Specifically, within the extracellular environment 
excess Ca++ ions and protons function to negate repulsive carboxylate interactions, 
stabilizing the virus particle. However, lower Ca++ ion concentrations and higher pH 
of the cellular environment results in the loss of stabilizing ions and protons, leading 
to particle disassembly and infection. Structural and mutational studies have 
identified three specific intersubunit carboxylate interactions within the TMV particle 
[96, 151]. One carboxylate interaction occurs between Asp116 and phosphate from 
the viral nucleic acid. Another forms a lateral cluster of interactions at the virion inner 
radius between E106 of one subunit and E95, E97 and D109 of the adjacent subunit. 
The third occurs axial between residues E50 and D77 (Figure  2-1A). The E50 – D77 
interaction has been shown to be a significant driver in helical rod assembly as 
mutations E50Q and D77N have been shown to block virus disassembly and produce 
empty virus-like helical rods during infection [96, 98, 161]. We have exploited these 
findings to investigate and develop an in vivo TMV VLP assembly system for the 







 TMV coat protein expression constructs 2.3.1.
 The TMV coat protein open reading frame (ORF) carrying the E50Q and 
D77N modifications was codon optimized for expression in E. coli (GenScript, 
Piscataway NJ: Supplemental Fig. 1) and inserted into the pET-21a(+) expression 
vector (Novagen, Madison WI) via NdeI and XhoI restriction sites. Further 
modifications to the N- and C-terminus of the coat protein ORF were achieved by 
primer based PCR mutagenesis using oligonucleotides containing additional or 
altered sequences (Table 1). A cysteine codon was added at position two at the N-
Figure 2-1: Carboxylate modifications to the TMV coat protein promote particle assembly. A, Molecular model 
of the rod surface showing the location of the juxtaposed E50-D77 carboxylate pair. B, Electron micrograph of 
crude bacterial lysates derived from the expression of the E50Q / D77N coat protein ORF. C, Electron 
micrograph of crude bacterial lysates from the unmodified coat protein showing only disks and short stacks of 





terminus of the coat protein ORF to produce TMV-VLP1cys for enhanced metal 
coatings and oriented surface-binding [162]. Sequences encoding the binding peptides 
for FLAG epitope (DYKDDDDK) were added to the coat protein C-terminus [163]. 
Sequences binding the fluorescent imaging agent GenhanceTM 680 (IQSPHFF) were 
added to the coat protein C-terminus as fusions either with or without preceding 
sequences encoding a “leaky” amber stop codon (TAG) or a flexible 10 amino acid 
linker (GGGGSGGGGS) [164], [165]. Amplified PCR products containing 5ʹ NdeI 
and 3ʹ XhoI restriction sites were used to ligate the modified coat protein ORFs into 
similarly cut pET-21a(+) vector. 
 Induction and purification of TMV-VLPs 2.3.2.
 Coat protein expression constructs were transformed into BL21 competent E. 
coli K-12. Additionally, JM109 E. coli cells were used for coat protein constructs 
containing the amber stop codon TAG. JM109 cells carry the supE44 suppressor of 
the amber stop codon via a tRNA mutation that transitions the GUC glutamine 
anticodon to AUC [166]. Transformed cells were cultured at 37oC in LB broth 
containing ampicillin (100 μg/ml) / chloramphenicol (50 μg/ml) for BL21 and 
ampicillin (100 μg/ml) / nalidixic acid (30 μg/ml) for JM109 cells to an OD600 of 0.5. 
Cells were then induced by the addition of 0.1 mM IPTG and incubated overnight at 
25°C. Induced cells were harvested by centrifugation at 4°C and lysed using 
BugbusterTM with LysonaseTM according to the manufacturer’s protocol (Novagen, 
Madison WI). Dithiothreitol to a concentration of 0.5 mM was added to the cell 
lysates followed by 3-5 min of sonication in a Branson 1510 sonicator (Branson 





lysates, mixed and separated by centrifugation for 10 min at 17,000 × g at 4°C. 
Because of the hydrophobic nature of the IQ peptide the chloroform purification step 
was replaced by centrifugation at 800 × g for 1 min, centrifugation of the resulting 
supernatant at 66,400 × g for 30 min, and resuspension of the pellet in 3 mL of 0.1 M 
pH 7 sodium phosphate buffer. VLPs were then precipitated by the per volume 
addition of 1.5% KCl and 6% polyethylene glycol for one hour at 4°C. VLPs were 
then pelleted by centrifugation for 10 min at 17,000 × g. The resulting pellet was 
resuspended by shaking overnight in 0.5 to 2 mls of 0.1 M pH 7 sodium phosphate 
buffer. Resuspended VLP pellets were then loaded onto a 10 to 40% sucrose gradient 
in 0.1 M pH 7.0 sodium phosphate buffer and centrifuged for 1 hr at 91,000 × g at 
14°C. A diffuse band corresponding to the purified VLP was removed by syringe and 
concentrated by centrifugation for 1 hr at 92,000 × g at 4°C. The purified VLP pellet 
was then resuspended in 0.1 M pH 7 sodium phosphate buffer.  
To visualize VLPs within bacteria, cells were induced overnight and 
subsequently prepared by pelleting, followed by fixing in 2% gluteraldehyde in 
phosphate buffered saline (PBS) with 0.29 M sucrose. Post-fixing was done in en 
bloc on the pelleted cells using 1% osmium tetroxide with 2% aqueous uranyl acetate. 
Dehydration of the pelleted cells was accomplished by treatment with solutions of 
increasing ethanol content (100% final). The dehydrated pellet was then embedding 
by solutions of propylene oxide with increasing Spurr’s resin content (100% final) 
and curing at 70°C overnight. Expressed VLPs were visualized in whole fixed 






 VLP surface assembly and electroless plating 2.3.3.
 Purified TMV-VLP1cys was self-assembled onto 1 cm2 gold-coated silicon 
chips by incubation overnight at 4°C in a 1 mg/mL solution of the purified VLPs 
resuspended in 0.1 mM sodium phosphate buffer, pH 7. VLP assembled chips were 
then dipped in a 0.158 mM solution of Na2PdCl4 for 30 minutes at 4°C. The surface-
bound VLPs were then coated with nickel by moving the chip directly into an 
electroless nickel plating solution consisting of 0.05 M NiCl2, 0.12 M glycine, 0.0785 
M sodium tetraborate, 0.525 M dimethylamine borane complex at pH 7. Nickel 
deposition by reduction was allowed to proceed at room temperature until the entire 
surface of the chip had darkened. Nickel coatings were visualized via field emission 
electron microscopy. 
 Chip based enzyme-linked immunosorbent assay (ELISA) 2.3.4.
 Gold coated 1cm2 silicon nitrate chips were submerged overnight in purified 
TMV1cys-VLP or TMV1cys-VLP1cys-FLAG at 4°C to facilitate oriented VLP 
assembly onto the gold surface. VLP assembled chips were then incubated for an 
additional 30 min at 4°C in Tris buffered saline (50 mM Tris-HCL, 200 mM NaCl, 
TBS) pH 7.0 containing 5% non-fat dry milk as a blocking agent. Chips were then 
rinsed three times by submersion in fresh TBS buffer. Rinsed chips were 
subsequently incubated for 3 hrs at room temperature in TBS containing 5% non-fat 
dry milk and a 1/1000 dilution of rabbit anti-flag antibody (Sigma-Aldrich, St. Louis 
MO). The chip was then rinsed 3 times with TBS buffer and twice with TBS buffer 
containing 0.05% Tween-20. After rinsing, chips were submerged in TBS with 5% 





and incubated at room temperature for 3 hrs. Chips were again rinsed as described 
above and placed directly in a solution containing 0.15 mg/ml of 5-bromo-4-chloro-3-
indoyl phosphate and 0.3 mg/ml NitroBT in substrate buffer (10 mM Tris-HCL pH 
9.5, 100 mM NaCl and 5 mM MgCl-6H2O) and incubated for 10 min at room 
temperature. The reaction was stopped by immersion in water and the chips dried. 
Color intensities of individual chips were measured using ImageJ software [167].  
 Fluorescence binding onto IQ peptide tagged TMV-VLPs 2.3.5.
 The IQ-tag modified VLPs were tested for preferential binding of the 
fluorescent imaging agent GenhanceTM 680 (PerkinElmer, Waltham MA) as follows. 
Purified TMV1cys-VLP-AmberFlex-IQ (0.2 mg/ml or 0.02 mg/ml) were incubated 
overnight at 4°C in 0.5 mL of 0.1 M pH7 phosphate buffer with or without the 
addition of 10 μL of 0.1 mg/mL GenhanceTM 680. Samples were then centrifuged at 
16,000 × g for 45 min. The VLP pellets were then resuspended in 1 mL of 0.1 M pH 
7.0 phosphate buffer and centrifuged again for 45 min. Pelleted VLPs were then 
resuspended in 0.1 M pH 7.0 phosphate buffer to a concentration of 0.5 mg/mL and 
0.05 mg/mL. 200 μL of each sample was added to a black-walled 96-well microtiter 
plate and fluorescence intensity at 690 nm (655 nm excitation and a 665 nm cutoff) 






 Expression and characterization of modified TMV coat 2.4.1.
protein VLPs 
 The TMV coat protein open reading frame was codon optimized for 
prokaryotic expression and synthesized either with or without E50Q and D77N 
substitutions (Supplemental Fig. 1). Bacterial expression of the modified coat protein 
open reading frames was achieved via IPTG inducible bacterial expression vectors. 
Induced bacterial cultures were lysed and the crude extracts analyzed for TMV coat 
protein expression and assembly. PAGE analysis of bacterial lysate demonstrated 
coat protein expression (Figure  2-2A, lane 2). Electron microscopy demonstrated the 
presence of rod-shaped VLPs consistent with the helical assembly of the TMV coat 
protein (Figure  2-1B). In contrast, the unmodified wild-type optimized TMV coat 
protein ORF produced only disks and stacks of disks when similarly expressed 
(Figure  2-1C). Subsequent thin section electron microscopy of induced bacterial cells 
also displayed the presence of rod-shaped TMV-like particles within the bacterial 






Figure 2-2: Expression and purification of TMV-VLPs from E. coli extracts. A, PAGE analysis of VLP purification 
scheme. Lane 1, protein marker; lane 2, lysed extract from IPTG induced bacteria; lane 3, chloroform clarified 
extract; lane 4, supernatant from PEG precipitation; lane 5, pellet from the PEG precipitation; lane 6, 
supernatant from the sucrose fractionation; lane 7, pellet from the sucrose fractionation. B, Agarose gel 
electrophoresis of RNA extracts from purified TMV-VLPs (Lane 1) and TMV virions (Lane 2). Band in lane 2 
represents the TMV genome. C, Thin section electron micrograph of a fixed E. coli cell showing the presence of 
assembled TMV-VLPs. D, Purified TMV-VLPs from the sucrose gradient resuspended pellet. Bars equal 200 nm. 
E, Transmission electron microscope images of TMV1cys (top row) and TMV1cys-VLP (bottom row) adjusted to 





Purification of these particles was easily accomplished via sucrose gradient 
centrifugation of chloroform cleared bacterial extracts. PAGE analysis from each 
purification step (bacterial lysate, chloroform clarification, PEG precipitation and 
sucrose gradient fractionation) shows the selective purification of the VLPs 
(Figure  2-2A, lanes 3-6) while electron microscopy of the final gradient fractions 
(Figure  2-2A, lane 7) shows the purity of the VLPs (Figure  2-2D). Concentrations of 
purified rod-shaped VLPs of over 70 mg per liter of culture were routinely obtained 
using this method. An analysis of purified particles indicated a width (18 nm) and 
inner channel size (4 nm) consistent with the virus particle. However, the length of 
the bacterial purified particles was highly variable with many particles substantially 
longer than the 300 nm virus produced particles (Figure  2-2D). Variable VLP lengths 
indicate an absence of RNA, which typically controls virus particle length. 
Subsequent nucleic acid extractions from purified VLPs confirmed the lack of nucleic 
acid in these particles (Figure  2-2B, lane 1). In contrast, similar nucleic acid 
extractions from purified virus samples produced an abundant amount of genomic 
viral RNA (Figure  2-2B, lane 2). Combined these findings demonstrate that the E50Q 
/ D77N mutations are sufficient to drive the nucleic acid free assembly of the TMV 
coat protein within the bacterial expression system. 
To determine the relative pH-dependent stability of the TMV and TMV-VLP 
rods, samples were exposed to a pH range of 3-11. 100 µL of 1 mg/mL TMV1cys and 
TMV1cys-VLP in 0.1 M pH 7 phosphate buffer were first dialyzed against 200 mL 
0.1 M pH 7 Tris. The samples were then divided and dialyzed against 200 mL 0.1 M 





examined by transmission electron microscopy. The results showed a similar stability 
profile for TMV1cys-VLP as compared to RNA-containing virus rods (Figure  2-2E). 
Both were shown to be stable at pH 5 and 7, with longer rods present at pH 5, and 
both exhibited fracturing of rods at pH 3 and 9. Both samples at pH 11 showed 
complete loss of visible structure. 
 Surface attachment and inorganic coatings of TMV1cys-2.4.2.
VLPs 
 To examine the stability of the bacterial assembled TMV-VLPs we assessed 
their ability to be surface assembled and metal coated. Previous studies using the 
TMV1cys virus have demonstrated a robust ability of this virus to bind surfaces in an 
oriented fashion (from one end of the rod) and via electroless plating produce uniform 
metal coatings [162, 168]. The positioning of the N-terminus 1cys mutation directs 
the attachment and vertical positioning of the viral rod-shaped particles onto gold, 
steel, or other metal surfaces [162]. Although surface exposed, the 1cys mutation is 
recessed within a groove and partially covered by the C-terminal arm of the coat 
protein. This position inhibits direct contact between the cysteine derived thiol and 
metal surfaces except at the 3ʹ end of the virion rod where the thiol group is 
sufficiently exposed to make direct contact with the gold surface (A). Here we show 
that the addition of the 1cys mutations to the E50Q / D77N TMV-VLP ORF produces 





easily metal coated using established electroless plating methods (Figure  2-3B) [162]. 
These findings demonstrate that even in the absence of viral RNA the E50Q – D77N 
VLP rods maintain robust stability during the extensive processing required for 
surface attachment and metallization.  
 Chip based enzyme linked immunosorbent assay 2.4.3.
 To examine the flexibility of the TMV-VLP assemblies we produced a set of 
modified coat protein ORFs for the display of peptides along the outer surface of the 
virus particle (Figure  2-4). The simplest system directly fused the peptide of interest 
to the C-terminus coat protein ORF so that each coat protein subunit displays the 
desired peptide (Figure  2-4A and B). For these experiments the eight amino acid 
FLAG peptide (DYKDDDDK) was fused directly to the C-terminal arm of the 1cys 
coat protein ORF to produce TMV1cys-VLP-FLAG. To examine the ability of 
Figure 2-3: Surface binding and electroless plating of TMV1cys-VLPs. A, Molecular models showing the location 
and binding of the TMV1cys-VLP modification for the oriented attachment of the VLPs onto a gold coated 






TMV1cys-VLP-FLAG assembled peptides to bind their target molecules we utilized 
a microchip based ELISA strategy for SiN chips [169]. TMV1cys-VLP-FLAG were 
self-assembled onto gold coated chips and washed with PBS buffer to remove any 
excess unbound virus and blocked with 5% non-fat milk to reduce background. 
Incubation with anti-FLAG antibody and subsequent detection via an alkaline 
phosphatase linked anti-antibody produced a clear color precipitant with an antibody 
detection limit of <10-6 mg/ml (Figure  2-5). Control chips assembled with TMV1cys-
VLP without the FLAG peptide did not show detectable color changes. These studies 
demonstrate the utility of the TMV1cys-VLP system for the display and surface 






Figure 2-4: TMV-VLP expression constructs. A, Diagram of TMV ORF with three variations for the expression 
and display of functional peptides. B, Western blot analysis of purified TMV1cys-VLP-FLAG particles with 
either anti-coat protein and anti-FLAG antibody. Lane 1, marker proteins; lane 2, the unmodified TMV1cys-
VLP; lane 3, TMV1cys-VLP-FLAG. C, PAGE analysis of purified TMV1cys-VLP-AmberIQ and -AmberFlexIQ 
constructs. Lane 1, marker proteins; lane 2, the unmodified TMV1cys-VLP; lane 3, TMV1cys-VLP-AmberIQ; 






 Controlled peptide display for VLP assembly small molecule 2.4.4.
detection 
 To further investigate the ability of the TMV-VLP system to function as a 
nano-scaffold for the display of functional peptides we engineered the rod-shaped 
VLPs to display a seven amino acid “IQ” peptide (IQSPHFF) previously identified by 
phage display for its ability to bind the fluorescent imaging molecule GenhanceTM 
680 [165]. However, initial attempts to purify TMV1cys-VLP rods with the IQ 
peptide fused directly to the C-terminus of the coat protein ORF failed (data not 
shown). We speculate that unlike the FLAG peptide the IQ peptide produces 
Figure 2-5: Use of TMV1cys-VLPs in a chip based ELISA detection system. A, Diagram of VLP assembly and 
detection system. B, Gold coated chips assembled with a range of TMV1cys-VLP-FLAG concentrations and 
processed as outlined in A. Note, the control chip coated with the 10-2 mg/ml unmodified TMV1cys-VLP did 





misfolding of the coat protein and / or disrupts VLP rod assembly, possibly via steric 
hindrance between the stacked coat protein subunits. To circumvent these potential 
problems an amber stop codon was added to the 3ʹ end (C-terminus) of the coat 
protein ORF (Figure  2-4A). Expression of the amber stop construct from within the 
bacterial supE44 suppressor system directs the occasional incorporation of a 
glutamine residue at the TAG stop codon due to a tRNA mutation. This produces a 
mixture of coat proteins both with and without the additional peptide. A second 
construct adding a 10 amino acid flexible linker “Flex” (GGGGSGGGGS) in front of 
the IQ peptide was also created as a means to further reduce any interference the IQ 
peptide may have on VLP rod assembly (Figure  2-4A). The small side chains of this 
linker produce a highly flexible peptide sequence that has been used extensively for 
bridging functional peptide domains [164]. Bacterial expression and subsequent VLP 
rod purifications produced significant quantities of these VLPs (Figure  2-4C). In 
particular the TMV1cys-VLP construct expressing the amber stop with flexible linker 
produced nearly twice the concentration of purified VLPs, ~16mg/L, in comparison 
to the construct with only the amber stop, ~9mg/L. For both constructs an average 
~34% of the subunits derived from the purified VLP nanorods were read-through 
products of the amber stop codon and displayed the additional peptide sequences 
(Figure  2-4C, lanes 3& 4). The ability to vary the expression and display of the 
desired peptide provides a means to significantly reduce disruptions in VLP assembly 
conferred by the desired peptide.  
The ability of the TMV1cys-VLP displayed IQ peptides to bind their target 





mixed with GenhanceTM 680, washed and analyzed for retention of the fluorescent 
imaging agent. Results for the tested VLP concentrations indicate that the VLPs alone 
are capable of binding low levels of the fluorescent analyte in a non-specific manner 
(Figure  2-6). However, addition of the IQ peptide sequence, creating TMV1cys-VLP-
AmberFlexIQ, produced a significant increase in retained fluorescence over the 
unmodified control TMV1cys-VLP (Figure  2-6). This finding indicates that the IQ 
peptide maintains the ability to bind its target molecule when displayed from the 
TMV1cys-VLP-AmberFlexIQ scaffold.  
 
 Discussion 2.5.
 In this study the known structure and assembly mechanism of TMV was used 
to engineer a novel in vivo VLP assembly system. In nature TMV occurs as a 
Figure 2-6: TMV-VLP directed binding of a fluorescent imaging agent. Purified TMV-VLPs at defined 
concentrations were mixed with Genhance 680TM (GH) washed and assayed for fluorescence retention. Data is 
shown for the unmodified TMV-VLP (VLP) and TMV-VLP-AmberFlexIQ (VLP-AmberFlexIQ) both with and 





soilborne virus and has evolved a sensitive sensing system that allows the rod-shaped 
particle to remain stable in the soil environment yet become unstable upon entry into 
a host cell. This sensing system is controlled by juxtaposed carboxylate interactions 
that exist between subunits [151, 161]. These repulsive carboxylate interactions 
represent a key factor in virion assembly and disassembly. Removal of these 
interactions strengthens the association of the coat protein subunits through existing 
hydrophobic and salt bridge interactions, significantly stabilizing the helical rod 
assembly [98]. Carboxylate alterations E50Q and D77N significantly shift the coat 
protein assembly equilibrium toward the production of rod-shaped particles, thus 
driving helical rod assembly even in the absence of the viral RNA. This modification 
permits the production of rod-shaped TMV-VLPs from a simple E. coli expression 
system and greatly expands the potential usefulness of these bio-macromolecules in a 
number of nanotechnology related applications.  
Significantly, the ability to rapidly produce quantities of TMV nanorod VLPs 
directly from bacterial cultures greatly simplifies methods for the construction and 
purification of highly modified versions of these macromolecules. The use of this 
system eliminates problems such as recombination and reduced virus accumulations 
that can occur when the infectious virus functions as the template for the display of 
functional peptides and groups. Additionally, specialized plant growth facilities are 
not needed, making these macromolecules more accessible for use in a wider range of 
research settings. Furthermore, findings indicate that bacterially expressed TMV-
VLPs display a similar level of stability and functionality as the plant produced 





functions. Thus, stability conferred by the genetic neutralization of repulsive 
carboxylate groups is sufficient to produce robust VLP assemblies.  
 For virus particles two areas of application that have been studied extensively 
are their use in materials fabrication and their ability to display functional groups for 
sensor or vaccine applications. Filamentous viruses including TMV and M13 have 
been developed as biotemplates for the deposition of a variety of inorganic materials 
[146, 150]. The rigidity of the TMV rod-shaped particle as well as its polar ends 
allows for the particle to be attached to a surface in vertical orientation, producing 
three-dimensional nano-featured substrates that significantly improve electrode 
function in a variety of electrode chemistries [150]. Similarly, TMV particles and coat 
protein have been genetically engineered to display epitopes from a variety of agents 
including the malaria parasite, foot and mouth disease virus and influenza A as a 
means to rapidly produce vaccine components [170-172]. Findings from this study 
clearly indicate that the TMV-VLPs are similarly capable of functioning as 
biotemplates for inorganic coatings as well as nanoparticles for the display of 
functional epitopes.  
 The use of bacterial phage and related systems to display and screen peptide 
libraries is a powerful combinatorial technology for the identification of unique 
peptides that confer selective binding abilities [173]. To date, phage display methods 
have been employed to identify numerous single chain antibodies as well as receptor 
peptides that bind various pathogens and toxins of importance, including heavy 
metals such as cadmium; toxins such as ricin, botulinum, shiga and staphylococcal 





179]. Many of these receptor peptides display binding affinities in the nano-molar 
range and are capable of detecting their target molecules in traditional ELISA systems 
at the nanogram level [165, 180]. However, a considerable gap between the 
identification of these receptor peptides and their assembly into functional devices 
remains. The TMV1cys-VLP based display system represents a simple means to 
genetically produce these peptides in a variety of configurations and in a 
nanostructured format that can be patterned three dimensionally onto a variety of 
surfaces. Combined these attributes make this VLP system a powerful means for the 
controlled display of functional peptides.  
 Conclusion 2.6.
 We report here the development of a TMV-VLP display system that directs 
the in vivo production of virus-like nanorods and tubes from a simple bacterial 
expression system. This system is genetically tractable and produces stable rod-
shaped VLPs that can be used to display functional groups and peptides in multiple 
configurations with potential applications in sensor, electrode and therapeutics 
development. This VLP system greatly simplifies the production of these rod-shaped 
particles, eliminating the need to produce a full-length infectious clone of the virus 
for production in plants. This simple, genetically tractable system for the production 
of TMV based nano-particles should provide greater accessibility for a wider core of 
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Chapter 3: Modified Tobacco Mosaic Virus Capsid 
Proteins with Unique Environmentally Responsive 
Assembly Behavior for Hierarchically Ordered 
Nanotubes 
 Abstract 3.1.
 The creation of particles and surfaces with complex functional architectures at 
the nanometer to micrometer scale is a promising capability afforded by advances in 
nanotechnology. One strategy for generating these materials is the hierarchical, 
bottom-up self-assembly of nanoscale components that occur naturally in biological 
systems. Tobacco mosaic virus (TMV) is one example of a self-assembling biological 
system that has been studied extensively for nanoscale applications. TMV is a 
filamentous plant virus with a hollow, tube-shaped rod of 300nm length × 18nm 
diameter consisting of ~2130 capsid protein [182] subunits. Its high aspect ratio and 
high surface area generated from iterated copies of a single component protein make 
it attractive as a foundation for the design of novel nanostructured materials. Multiple 
acidic amino acid residues are incorporated into the viral CP, generating electrostatic 
repulsion between adjacent CP not only within the assembled rod, limiting assembly 
of virus rods without incorporated genomic RNA, but also between individual rods, 
encouraging their monodispersity. One pair of negatively charged, surface-exposed 
residues known to have particular importance to the virus’s structural stability 
through electrostatic repulsion is composed of glutamic acid E50 and aspartic acid 
D77, which are shown by structural analysis to interact between adjacent CP in the 





effects of altering these residues on the assembly behavior of TMV CP both within 
individual rods for the generation of a new class of virus-like particles (VLPs) and 
between different members of this class for the self-directed, hierarchical assembly of 
more complexly structured nanoparticles. Replacing the one or both of the negative 
charged carboxylate residues glutamic acid (E50) and aspartic acid (D77) with 
neutrally charged glutamine (E50Q) and asparagine (D77N) or positively charged 
lysine (E50K or D77K) results in self-assembling nanotube VLPs with unique rod 
end charge profiles which self-direct the end-to-end coassembly of distinct VLP 
populations into lengthened, chimeric VLP with longitudinally ordered structure. 
Addition of a well-positioned cysteine residue directs the perpendicular attachment of 
these complex VLPs to surfaces to for the development of surface-attached 
nanoscaffolds with distinct surface-proximal and surface-distal addressability and 
functionality. 
 Introduction 3.2.
Biologically derived macromolecular assemblies are of increasing interest for 
their application in nanotechnology. Nucleic acids, proteins, and complexed 
assemblies of these, such as viruses, have been investigated for applications including 
enhanced energy production, sensing, drug delivery and enzyme sequestration [183-
185]. Interest in these biological components stems from their ability to self-assemble 
into defined nanoscale structures, to recognize and bind target analytes, to 
enzymatically catalyze chemical reactions, and to be manipulated genetically, 
permitting specific modifications to these assemblies. In addition, the bottom-up 





to generate novel nanoscale structures and patterns with unique functions. Examples 
include “DNA origami” that utilize DNA base paring to direct the ordered assembly 
of hundreds of oligonucleotides or the use of protein–protein interaction domains to 
assemble peptide chains into complex geometric shapes [185-187]. Combined, these 
studies represent remarkable initial efforts in the development and application of 
designed biological assemblies.  
Viruses in the form of virions represent some of the most studied and 
manipulated naturally occurring sub-micron self-assembly systems. As such, virus-
based assembly systems have been created to encapsidate therapeutics, enzymes, 
pesticides and inorganics for use in a range of applications [188-190]. What make 
viruses particularly amenable to these studies are the molecularly scaled uniform 
capsid proteins that under the appropriate environmental conditions can be induced to 
self-assemble into defined nanoscale shapes with great fidelity. In general, 
modification of virion assemblies has involved the surface display of naturally 
occurring or genetically introduced amino acid residues or functional polypeptide 
chains that enable chemical cross-linking of molecules to the virion surface, the 
surface display of selective binding motifs or the incorporation of enzymes, nucleic 
acids and inorganics within the virion shell [183, 191]. These studies add 
functionality to existing virion structures, but efforts to re-engineer virion assembly to 
produce novel nanoscale structures are less well developed and in need of additional 
investigation.  
Some of the most extensive efforts to modify virion assembly have occurred 





environmental systems. The TMV particle consists ~2130 identical coat proteins 
subunits (M.W. 17.5 kDa) packed in an 18 nm diameter helix, the layers of which 
sandwich a single strand of plus-sense RNA, around a 4 nm diameter channel situated 
along the 300 nm long longitudinal axis [151]. The two ends of the rod-shaped virion 
are morphologically distinct, with a concave surface at the end containing the 5ʹ end 
of the genome and a convex surface structure at the 3ʹ genome end. The three-
dimensional structure of the CP has been resolved to 2.8 Å and 2.4 Å for a 20S disk 
aggregate, consisting of two stacked protein rings each containing 17 CP subunits 
[82, 160] and at 2.9 Å resolution for the TMV virion [151]. This structural 
information has led to several innovative assembly systems. Included in these systems 
is the design of a circular permutant from a rearrangement of the TMV CP gene with 
newly created N- and C-termini on the inner - rather than outer - surface, facilitating 
modifications to the central channel of the virion [157]. In a second system an added 
cysteine at inner-channel-proximal CP residue 103 was used to promote the assembly 
of rod shaped virus-like particles (VLP) in the absence of viral RNA [192]. The 
disulfide bonds responsible for stabilizing rod assemblies provide a redox-based 
means to control the production of virus-like protein rods. Alternatively, novel 
assembly systems have been developed by altering the viral RNA, which plays a 
critical role as a structural component of the virion. Specifically, RNAs containing 
TMV origin of assembly sequences (OAs) can be used to direct the assembly of TMV 
CPs into virus-like rods of defined lengths, heterologous CP composition or onto 
patterned substrates [193-195]. Furthermore the multiple-OAs-containing-RNA-





structures [196]. Combined these systems provide varying levels of control over the 
assembly of these virus-based macromolecular assemblies, opening up their potential 
as functional components in larger and more complex nano- and micro-scale 
structures.  
Our group has previously developed a VLP assembly system based on the 
elimination of an assembly-destabilizing intersubunit interaction between carboxylate 
groups [181]. Previous studies had identified two sets of carboxylate groups 
generating intersubunit repulsion, composed of (i) CP residues E50 and D77 
interacting between axially adjacent subunits and (ii) E106 and E95/E97/D109 
located between laterally adjacent subunits, as providing the driving forces in virion 
disassembly [96, 151, 161]. Outside of a host cell, the relatively low pH of the 
extracellular environment functions to neutralize this repulsive E50 – D77 interaction, 
stabilizing the virion assembly. However, upon entry into the cellular environ the 
higher pH results in the loss of stabilizing protons and the destabilization and 
disassembly of the virion. By weakening these repulsive interactions, substitution 
mutants E50Q/D77N, E97Q, and E95Q/D109N function to stabilize the virion 
assembly, producing long virion-like rods in planta [96]. In addition, the double 
axially-interacting-carboxylate substitution E50Q/D77N produces long virion-like 
rods in bacterial expression systems [181]. The use of bacterial systems greatly 
enhances the speed and ease of expression for these TMV-VLPs over plant-based 
TMV infection systems. In addition, heterologous expression is significantly more 
amenable to incorporation of additional gene-level modifications since recombination 





In this study, the directed modulation of TMV-VLP assembly is investigated 
as a means to control the production of complex hierarchical nano-rods. Genetic 
modifications of the TMV CP were created to modulate both the CP subunit structure 
and its electrostatic-charge-based intersubunit interactions to either strengthen or 
weaken the ability of individual CP interfaces to self-associate and to associate with 
other modified or wild-type CP. These modifications were created to preferentially 
direct assembly of CP subunits to either the 3ʹ or 5ʹ nanorod ends of TMV. 
 Methods 3.3.
 Design of modified TMV CP genes  3.3.1.
The TMV capsid protein gene was modified to substitute neutrally charged or 
basic amino acid residues for one or more of the negatively charged acidic residues 
which interact with those on adjacent CP subunits. All modified forms of the TMV 
capsid protein used in this study were ultimately generated from copies of a DNA 
open reading frame (ORF) encoding the TMV CP codon optimized for expression in 
E. coli using codon utilization frequency tables. The ORF encoding the E50Q/D77N 
form was obtained from GenScript (Piscataway, NJ). The ORFs encoding the 
E95Q/E97Q/E106Q/D109N, E50Q+E95Q/E97Q/D109N, D77N+E106Q, E50K-HA, 
and D77H and R46G-E50H-HA were generated using Invitrogen™ GeneArt™ 
Strings™ DNA fragments. All additional variants were generated by sequential 
polymerase chain reactions using overlap extension PCR with primers encoding the 
designed modifications and complimentary to regions of the ORF to be modified. 
These included additional modifications to the carboxylate-containing sites E50, D77, 





“1cys”) modification by the insertion of a cysteine at position three (5ʹ-MSYS…5ʹ-
MSCYS…), and insertion or replacement of sequences encoding either the FLAG-tag 
epitope (DYKDDDDK) or the HA-tag (YPYDVPDYA) to the 3ʹ end of the gene, 
following the sequence encoding the C-terminal PAT residues. Two endonuclease 
restriction sites, an NdeI restriction site over lapping the ORF start codon and an XhoI 
restriction site at the 3ʹ end, flanking the ORF were included. For each ORF-interior 
modification, a set of PCR reactions, each using a primer pair consisting of either a 
forward primer containing the ORF 5ʹ end and a reverse primer containing the interior 
modification or a forward primer containing the interior modification and a reverse 
primer containing the ORF 3ʹ end, was performed using Platinum Taq DNA 
Polymerase (Invitrogen): 94 °C for 5min; 32 cycles of 94 °C for 30 s / 55 °C for 30 s / 
72 °C for 1 min; 72 °C for 5 min). The PCR product from each of the two PCR 
reactions was gel-purified using a GENECLEAN III gel purification kit (MP 
Biomedicals) and used as templates for PCR with the 5ʹ end forward primer and the 3ʹ 
end reverse primer from the previous PCR reactions. Complete PCR products of CP 
ORFs were isolated and amplified using a TOPO TA cloning kit. pCR-2.0 vector, 
TOP10 competent cells (Invitrogen). 
ORFs were excised from TA clones by restriction with NdeI and XhoI and 
isolated from the plasmid vector by agarose gel electrophoresis. Bands were purified 
using GENECLEAN III gel purification kit and purified DNA fragments were ligated 
into a similarly cut and purified pET-21a(+) (Novagen, Madison, WI) or pET-DUET 
expression vector with T4 DNA ligase. Complimentary overhangs between vector 





vectors containing the ORFs were transformed into DH5α chemically competent cells 
for amplification with ampicillin selection and subsequent miniprep purification. 
Clones containing inserted genetic material were identified using restriction 
hydrolysis of ORF-flanking restriction sites and were sequenced to screen for 
unintended mutations.  
 Bacterial expression and purification of TMV CP variants 3.3.2.
 Plasmids containing sequence-verified ORFs encoding the various TMV CPs 
described above were transformed into chemically competent BL21-CodonPlus E. 
coli K-12 cells. Transformations were spread onto LB-agar plates containing 
ampicillin (100 µg/mL) and chloramphenicol (20 µg/mL). Colonies were picked and 
grown in LB containing ampicillin (100 µg/mL) and chloramphenicol (20 µg/mL) at 
37 °C overnight. Frozen stocks of cells containing the TMV CP constructs for 
continued production of modified CP were made by addition of DMSO (70 µl/mL 
culture) and storage at -80 °C. Cell cultures were grown at 37 °C until reaching an 
absorbance of 0.5 ± 0.1 at a wavelength of 600 nm. At that point the culture was 
induced by the addition of IPTG to a concentration of 1 mM and incubated at room 
temperature with shaking overnight. Induced cells were pelleted by centrifugation at 4 
°C and lysed by resuspension in Bugbuster HT Protein Extraction Reagent and the 
addition of Lysonase according to the manufacturer’s protocol (Novagen, Madison 
WI) and incubation at room temperature for 30 minutes. The bacterial lysate was 
diluted 10:1 with 0.1 M pH 7 phosphate buffer and pelleted by centrifugation at 
91,000 × g for 2 hours. The resulting pellet was resuspended in 2 mL 0.1 M pH 7 





were loaded onto a 10 to 40 % sucrose gradient in 0.1 M pH 7 phosphate buffer and 
centrifuged at 91,000 × g at 14 °C for either 1 hour (E50Q and D77N variants) or 15 
minutes (E50K and D77K variants). The virus-like particles were removed from the 
center portion of the gradient, where they formed a diffuse visible band, with a 
syringe and transferred to ~25 mL ultracentrifuge tubes. The samples were diluted 
with 0.1 M pH 7 phosphate buffer to reduce sucrose concentration and centrifuged at 
91,000 × g for 2 hours at 4 °C. The purified VLP pellets were resuspended in 0.1 M 
pH 7 phosphate buffer. 
 Determining concentration of TMV and bacterially expressed 3.3.3.
TMV CP 
 All determinations of disassembled CP and assembled VLP solution 
concentrations were made using a Thermo Fisher Scientific™ Nanodrop™ 1000. 
VLP samples purified from monoclonal cultures of transformed expression strains of 
E. coli (BL21 and BL21 codon plus) all showed a light attenuation peaks at around 
280 nm, indicating the relative lack of nucleic acid and in contrast to purified samples 
of absorption spectrum of encapsidated RNA centered around 260 nm. 
 Determinations of TMV concentrations, which contain the genomic RNA, 
were made by measuring the attenuation of the TMV sample at λ = 260 nm, 
calculating and subtracting the attenuation due to scattering to obtain the attenuation 
at 260 nm attributable to absorbance alone and using the mass attenuation coefficient 







(𝐴𝐴260 − 2.44 × 𝐴𝐴325)
𝜀𝜀𝑇𝑇𝑇𝑇𝑇𝑇,260 × 𝑙𝑙
 
Where A260 and A325 are the sample absorption measurements of 260 nm and 325 nm 
wavelength light, respectively, εTMV,260 is the extinction/attenuation coefficient of 
TMV at wavelength 260 nm, and l is the path length. The expression 2.44 × A325 is 
the estimated attenuation at 260 nm due to scattering. Because neither protein nor 
RNA has significant absorption at 325 nm, all attenuation at 325 nm is assumed to be 
due to scattering. Because scattering varies with wavelength with a factor of λ−4,the 
scattering at 260 nm is related to the scattering at 325 nm by a factor of (260−4/325−4) 
= 2.44. The inherited mass attenuation coefficient for TMV, ε260, is 3 L∙g−1∙cm−1. 
 The concentration of RNA-free, bacterially expressed CP was determined by 
measuring the optical attenuation at λ = 280 nm, calculating and subtracting the 
attenuation due to scattering to obtain the attenuation  at 280 nm attributable to 
absorbance alone and using the mass attenuation coefficient and path length to 
determine concentration using the following form of the Beer-Lambert law 
𝐶𝐶 =  
𝐴𝐴280  −  (1.8 ×  𝐴𝐴325)
𝜀𝜀𝐶𝐶𝐶𝐶,280  ×  𝑙𝑙
 
Where A280 and A325 are the sample absorption measurements of 280 nm and 325 nm 
wavelength light, respectively, ε280, is the extinction/attenuation coefficient of the 
relevant CP at wavelength 260 nm (see table), and l is the path length. The expression 
1.8 × A325 is the estimated attenuation at 280 nm due to scattering. Because protein 
does not have significant absorption at 325 nm, all attenuation at 325 nm is assumed 





λ−4,the scattering at 280 nm is related to the scattering at 325 nm by a factor of 
(280−4/325−4) = 1.815.  
 The attenuation coefficients of the VLP-forming CPs were calculated using 
the Edelhoch method, according to which 
𝜀𝜀(208)(𝑀𝑀−1𝑐𝑐𝑐𝑐−1) = (#𝑇𝑇𝑇𝑇𝑇𝑇)(5,500) + (#𝑇𝑇𝑇𝑇𝑇𝑇)(1,490) + (#𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑙𝑙𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑)(125) 
where ε(280) is the molar attenuation coefficient, #Trp, #Tyr, and #disulfide are the 
number of tryptophan residues, tyrosine residues, and disulfide bonds bonds formed 
by crosslinked cysteine residues, respectively. The corresponding mass attenuation 
coefficients were obtained by dividing the molar attenuation coefficents by the mass 
in grams per mole of CP.  






Molar ε  
(M−1∙cm−1) 
FW Mass ε  
(L∙g−1∙cm−1) 
WT CP 3 4 0 22460 17420 1.289 
1cys CP 3 4 0 22460 17524 1.281 
R46G/E50K-
E97Q-FLAG 
3 6 0 25440 18405 1.382 
D77K-HA 3 5 0 23950 18429 1.299 
Table 2: Molar and mass attenuation coefficients at 280 nm for various TMV CPs. 
 Longitudinal coassembly of neutral carboxylate-substituted 3.3.4.
CP variants with TMV or VLP with wild-type axial 
carboxylates 
 Complexed nanoparticles with distinct and ordered longitudinal domains 
generated from the coassembly of a nanoparticle retaining wild-type axially 
interacting carboxylate residues (either infectious TMV or VLP assembled from 
E95Q/E97Q/D109N+E106Q CP) together with a VLP containing uncharged amino 





D77N+E106-HA VLP) were produced by concentration of a solution containing a 
mixture of the component nanoparticles.  
 For the longitudinal coassembly of TMV and D77N+E106Q-HA VLP, 100 µg 
each of purified 5 mg/mL 1cys TMV and D77N+E106Q-HA VLP in 0.1 M pH 7 
sodium phosphate buffer were mixed and diluted with 25 mL 0.1 M pH 7 sodium 
phosphate buffer in a ultracentrifuge tube. The mixture was centrifuged at 91,000 × g 
for 2 hours at 4 °C, at which point the supernatant was removed and replaced with 
100 µL of 0.1 M pH 7 sodium phosphate buffer. The pellet was allowed to resuspend 
overnight at 4 °C with gentle rocking, then diluted (1:500) in 0.1 M pH 7 phosphate 
buffer for immunolabelling and preparation for TEM. 
For the longitudinal coassembly of E95Q/E97Q/D109N+E106Q VLP with 
 E50Q+E95Q/E97Q/D109N-FLAG VLP, 50 µL of 1 mg/mL solutions of each 
of the two purified VLPs in 0.01 M pH 7 sodium phosphate buffer were well mixed 
in a 1.5 mL centrifuge tube. The mixed sample was then centrifuged under partial 
vacuum until the sample volume had reduced to ~10 µL (approximately one hour). 
The concentrated sample was kept at 4 °C overnight before dilution (1:500) in 0.1 M 
pH 7 sodium phosphate buffer for immunolabelling and preparation for TEM. 
 Dialysis of samples 3.3.5.
 All dialysis was performed Spectra/Por® dialysis membrane tubing 
(MWCO:12-14,000, Spectrum Labs) secured to the opening of a 1.5 mL 
microcentrifuge tube containing 50-200 µL of plant-expressed TMV and/or 
bacterially expressed CP. The microcentrifuge tubes were inverted so that sample 





holder on the surface of 500 mL of the solution to be dialyzed against, so that the 
dialysis tubing was in contact with the target dialysis solution. All dialysis was 
performed at 4 °C overnight. For all dialysis experiments, TMV or CP samples, 
which were initially in 0.1 M pH 7 sodium phosphate buffer were first dialyzed to 0.1 
M pH 7 Tris buffer. The pH 7 Tris-buffered samples were then dialyzed against either 
ultrapure water adjusted to pH 7 with approximately 50 µL of 12 M NaOH per 1 L of 
water or 0.1 M Tris adjusted to pH 5, 6, 7, 8, or 9 with glacial HCl or 12 M NaOH. 
 Longitudinal coassembly of positively-charged carboxylate-3.3.6.
substituted CP variants with TMV 
 To generate extended TMV-VLP complexed particles with distinct and 
ordered longitudinal components, TMV and VLP were dialyzed either separately or 
in admixture to solution conditions promoting disassembly of the VLP CP and then 
returned to conditions promoting its assembly, either by dialysis or by the addition of 
concentrated solution.  
 For assembly of D77K-HA CP onto TMV, 50 µL of a solution containing 3 
mg/mL of D77K-HA CP and 0.6 mg/mL wild-type TMV (a ratio of 5:1 by mass) in 
0.1 M pH 7 sodium phosphate buffer was dialyzed as described above first to 0.1 M 
pH 7 Tris buffer, then to 0.1 M pH 9 Tris buffer to disassemble the D77K CP, and 
then to 0.1 M pH 7 Tris buffer to initiate reassembly of the D77K CP onto the TMV 
rod end with each dialysis step taking place overnight at 4 °C. For samples treated 
with RNase, 0.5 µL of a 1 mg/mL stock solution of RNase A was added to the 





genomic RNA at the TMV’s 5ʹ rod end, and incubated for 30 min at 37 °C before 
proceeding with dialysis back to pH 7. 
 For assembly of R46G/E50K+E97G-FLAG CP onto TMV, 50 µL of a 
solution containing 1 mg/mL of R46G/E50K+E97G-FLAG and 0.5 mg/mL wild-type 
TMV (a ratio of 2:1 by mass) in 0.1 M pH 7 sodium phosphate buffer was dialyzed 
first to 0.1 M pH 7 Tris buffer, then to filtered ultrapure water brought to pH 7 with 
NaOH to disassemble the R46G/E50K+E97G CP, and then to 0.1 M pH 7 Tris buffer 
/ 0.3 M NaCl to initiate reassembly of R46G/E50K+E97G CP onto the TMV rod end 
with each dialysis step taking place overnight at 4 °C. 
 Immunolabelling and electron microscopy 3.3.7.
 To immunolabel and image samples, assembled TMV and VLP samples were 
adsorbed onto Formvar-coated Ni TEM grids by floating the grid on 5-10 µL droplets 
containing the sample arrayed on Parafilm™. Grids were washed with phosphate-
buffered saline (PBS: 10 mM sodium phosphate, 150 mM NaCl, pH 7). Surfaces were 
blocked with Blocking Solution for Goat Antibodies (Aurion, Wageningen, The 
Netherlands) to reduce nonspecific binding and washed with PBS. Primary antibodies 
(anti-FLAG antibodies produced in rabbit, anti-HA antibodies produced in mouse, 
Sigma) were diluted 1:500 in incubation buffer (PBS with 0.1% Tween-20 and 0.1% 
Aurion BSA-c™) as needed and applied to grids at room temperature for 2 h or at 4 
°C overnight. Grids were washed by placing on 50 µL drops of incubation buffer for 
5 min three times. Gold nanoparticle (AuNP)-conjugated secondary antibodies (i.e. 
goat anti-rabbit with 10 nm AuNPs or goat anti-mouse with 6 nm AuNPs), if used, 





temperature for 2 h or at 4 °C overnight. Grids were washed by placing on 50 µL 
droplets of incubation buffer for 5 min three times and then on 50 µL droplets of 0.1 
M pH 7 Tris. Grids were stained by placing them on a 5 µL droplet of 2% uranyl 
acetate (UAc) for 1 min. UAc was removed by wicking with filter paper, and the 
samples were imaged using a Zeiss transmission electron microscope (TEM) at 80 
kV. 
 Light scattering assembly kinetics 3.3.8.
Macromolecular assembly kinetics of the D77K and R46G/E50K+E97G CP 
from the disassembled to the assembled state upon lowering of the pH or increase of 
the ionic strength of the solution was observed in real time using 90° light scattering 
to measure the relative degree of rod formation in an aqueous solution of CP. Light 
scattering was measured on a Varian Cary Eclipse Fluorescence Spectrophotometer. 
Scattered light was measured at an angle of 90° relative to the angle of incidence 
using 200 µL of CP solution in a 200 µL capacity quartz cuvette and using the same 
value of 340 nm for the excitation and emission wavelengths. The dissociation factor 
D was related to the intensity of scattered light, I, by 
𝐷𝐷 = (𝐼𝐼𝐴𝐴 − 𝐼𝐼)/(𝐼𝐼𝐴𝐴 − 𝐼𝐼𝐷𝐷) 
where IA and ID are the intensity of scattered light for associated and dissociated 
forms, respectively. 
 For experiments examining D77K CP assembly, samples were measured by 
beginning recording of scattered light with baseline measurement of 175 µL of 0.1 M 
Tris buffer adjusted to pH 5. After 30 s, 25 µL of D77K-HA-tag CP previously 





pipetting. Light scattering was recorded for 20 minutes after mixing. 
 For experiments examining R46G/E50K+E97G CP assembly, samples were 
measured by beginning recording of scattered light with baseline measurement of 100 
µL of R46G/E50K+E97G-FLAG-tag CP previously dialyzed against filtered water 
adjusted to pH 7 with NaOH (~50 μL 12 M NaOH / 1 L H2O). After 30 s, 100 µL of 
0.2 M Tris buffer with 0.6 M NaCl adjusted to pH 9 was added and mixed by manual 
pipetting. Light scattering was recorded for 30 minutes after mixing. 
Data was obtained using 340 nm as both the “excitation” (incident light applied to 
sample from the light source) and “emission” (scattered light measured from sample) 
wavelength values. This wavelength was chosen after several experiments in which a 
scan of excitation and emission values were covaried through a range from 200 nm to 
700 nm every minute during an assembly reaction of D77K-HA CP. Significant 
changes in scattered light was observed in the ranges from ~240 nm to ~270 nm and  
from ~280 nm up to 700 nm, with a dramatically reduced level of scattering observed 
in the region around 280 nm, presumably due to the high level of absorption by 
sample CP. The wavelength 340 nm was selected from the candidate ranges as 
determined by observation due to its use in the literature as a value previously used to 
study the assembly state of TMV [197, 198]. 
 Surface-bound fabrication of co-assembled nanoparticles 3.3.9.
Gold-coated silica wafers (0.5 cm × 0.5 cm), cleaned by sequential 5 min 
submersions in acetone, methanol, and isopropanol with agitation, were submerged in 
either a 0.2 mg/mL solution of 1cys TMV in 0.1 M pH 7 sodium phosphate buffer or 





phosphate buffer was removed by submersion of the wafers in either 0.1 M pH 9 Tris 
for subsequent addition of D77K-HA CP or filtered water adjusted to pH 7 (by 
addition of ~50 μl 12 M NaOH /  1 L water using a pH-meter to monitor pH level) for 
subsequent addition of R46G/E50K+E97G-FLAG CP. 
For longitudinal coassembly of D77K-HA CP onto the TMV base layer: The 
wafers were placed gold-side-up on Parafilm™ in a 60 mm diameter petri dish. 5 μL 
of either 0.1 M pH 9 Tris or a 5 mg/ mL solution of D77K-HA CP previously 
dialyzed with 0.1 M pH 9 Tris to promote VLP disassembly was added to the gold 
surface by pipet and allowed to sit for 10 minutes at room temperature. Then 35 μL 
0.1 M pH 5 Tris buffer was transferred to the gold surface by pipet, and the petri dish 
was covered with the lid and transferred to 4 °C overnight.  
For longitudinal coassembly of R46G/E50K+E97G-FLAG CP onto the TMV 
base layer: The wafers were placed gold-side-up on Parafilm™ in a 60 mm diameter 
petri dish. 10 μL of either filtered water adjusted to pH7  or a 10 mg/ mL solution of 
R46G/E50K+E97G-FLAG CP previously dialyzed with filtered water adjusted to 
pH7 to promote VLP disassembly was added to the gold surface by pipet and allowed 
to sit for 10 minutes at room temperature. Then 10 μL 0.6 M NaCl, 0.2 M pH 7 Tris 
buffer was transferred to the gold surface by pipet, and the petri dish was covered 
with the lid and transferred to 4 °C overnight.  
Excess unbound CP was washed by submersion of the wafers in 1 mL 0.1 M 
pH 7 Tris (for D77K-HA CP samples) or 1 mL 0.3 M NaCl, 0.1 M pH 7 Tris (for 
R46G/E50K+E97G-FLAG CP samples) for 5 minutes. The wafers were then placed 





Aurion Blocking Solution for Goat Antibodies was gently layered onto each wafer 
and allowed to block for 1 hour at 4 °C. The wafers were then washed by submersion 
of the wafers in 1 mL 0.1 M pH 7 Tris (for D77K-HA CP samples) or 1 mL 0.3 M 
NaCl, 0.1 M pH 7 Tris (for R46G/E50K+E97G-FLAG CP samples) for 5 minutes, 3 
times. The wafers were again transferred to Parafilm™, and 50 μL of primary 
antibodies (anti-FLAG antibodies produced in rabbit, anti-HA antibodies produced in 
mouse, Sigma) diluted 1:1000 in incubation buffer (PBS with 0.1% Tween-20 and 
0.1% Aurion BSA-c™) was applied to each wafer at room temperature for 2 h or at 4 
°C overnight. The wafers were again washed 3 times for 5 minutes each in 1 mL 0.1 
M pH 7 Tris (for D77K-HA CP samples) or 1 mL 0.3 M NaCl, 0.1 M pH 7 Tris (for 
R46G/E50K+E97G-FLAG CP samples). The wafers were then submerged in 500 μL 
of a 1:1000 solution of secondary antibodies conjugated to horseradish peroxidase 
(anti-rabbit antibodies produced in goat in 0.1 M pH 7 Tris for D77K-HA CP samples 
and anti-mouse antibodies produced in goat in 0.3 M NaCl, 0.1 M pH 7 Tris for 
R46G/E50K+E97G-FLAG CP samples. The wafers were again washed 3 times for 5 
minutes each in 1 mL 0.1 M pH 7 Tris (for D77K-HA CP samples) or 1 mL 0.3 M 
NaCl, 0.1 M pH 7 Tris (for R46G/E50K+E97G-FLAG CP samples). The wafers were 
then submerged in 1 mL substrate buffer (0.1 M pH 7 Tris, 0.2 M NaCl and 5 mM 
MgCl) containing 0.15 mg/ml of 5-bromo-4-chloro-3-indoyl phosphate and 0.3 
mg/ml NitroBT. The submerged wafers were monitored for color change, and all 
wafers were removed and washed with 0.3 M NaCl, 0.1 M pH 7 Tris to halt 





 Results and Discussion  3.4.
 The role of carboxylate groups on TMV-VLP nanorod 3.4.1.
assembly 
Previous studies of TMV had identified carboxylate residues whose presence 
and mutual interaction was key to virion disassembly in host cells [97, 199]. Within 
the assembled TMV virion, each CP subunit interacts with its neighbors in the axial 
direction through the mutually repulsive interaction of D77 and E50 while in the 
lateral direction residue E106 interacts repulsively with neighboring cluster 
E95/E97/D109 to regulate assembly (Figure  3-1B). D77 and E106 sidechains are 
oriented toward and exposed on the virion end containing the 5ʹ RNA genome 
terminus (5ʹ rod end), while E50 and E95/E97/D109 sidechains are oriented toward 
and exposed on the opposite rod end containing the 3ʹ genome terminus (3ʹ rod end). 
To further explore the role these carboxylate groups played in directing protein 
nanorod assembly a bacterial expression system was used to generate wild-type and 
substitution-variant TMV CP from an open reading frame codon-optimized for 
bacterial expression. Initial studies demonstrated that CP modifications E50Q/D77N 
produced virus-like nanorods that were of similar stability to the virus nanorods with 
respect to pH conditions but devoid of RNA and thus lacking constraint over particle 
length, exhibiting a broad distribution of values but typically between 300 and 900 
nm [181] (Figure  3-2B). To examine the contributions of E50Q and D77N 
individually to nanorod assembly single mutations were made and the resultant CP 
expressed within the bacterial system. Results indicated that at pH 7 the E50Q 





phosphate buffer that were visually indistinguishable from the original E50Q/D77N 
CP (Figure  3-2D). In contrast, the D77N mutation on its own produced only two layer 
disks similar to the unmodified wild-type CP (Figure  3-2C). These results were 
consistent with previous findings that TMV with the E50Q mutation significantly 
reduced viral infectivity in planta and hindered in vitro translation of the embedded 
RNA genome with or without the D77N mutation, while the latter mutation alone did 
not [96]. 
 
 The E50 and D77 carboxylate groups interact in the direction of the virion 
axis between subunits in successive turns of the rod’s helical structure. There also 
exists a lateral interaction between E106 on one subunit and E95/E97/D109 of the 
next subunit within a turn of the helix at the low-radius region of the assembled 
Figure 3-1: (A) Model of assembled section of TMV with sections removed to show protein assembly structure. 
(B) Ribbon models of three axially adjacent (top) or laterally adjacent (bottom) TMV CP subunits as located 
within an assembled TMV rod. (C) Ball-and-stick models of axially interacting carboxylates E50 and D77 (top) 
and laterally interacting E95/E97/D109 and E016 (bottom). (D) TEM images of axial-carboxylate-substituted 
E50Q+D77N CP VLPs (top) and lateral-carboxylate-substituted E95Q/E97Q/D109N+E106Q CP VLP. 





nanorod. Neutralization of just the four laterally interacting carboxylates using the 
substitutions E95Q/E97Q/D109N+E106Q2 results in the self-assembly of rod-like 
VLPs from the bacterially expressed protein (Figure  3-1, bottom right). This indicates 
that the neutralization of the repulsive lateral interaction is sufficient to drive rod 
assembly and is consistent with the observed decrease in infectivity and translation of 
TMV with these same four substitutions. The combination of 3ʹ-end-exposed E50Q 
with 3ʹ-end-exposed E95Q/E97Q/D109N produced rods similar to E50Q alone. 
Interestingly, the addition of 5ʹ-end-exposed E106Q to the 5ʹ-end-exposed D77N 
produces rod assembly despite the reduced impact of this substitution (and lack of 
impact of the D77N substitution) on TMV infectivity in planta and translation in vitro 
relative to the E50Q (with or without D77N) and the E95Q/E97Q/D109N+E106Q 
substitutions. Combined these mutations demonstrate the contributions of these key 
carboxyl–carboxylate interactions in the control of VLP rod assembly. 
                                                 
 
2 A note concerning notational conventions in this chapter: the amino acid substitutions made to the 
TMV CP in this work are generally substitutions to one or more of four sets of carboxylate containing 
amino acid residues: (a) axially interacting E50, (b) axially interacting D77, (c) the laterally interacting 
group E95, E97, and D109, and (d) laterally interacting E106. The notations for multiple substitutions 
within a set are separated by slashes (“E95/E97/D109”), while substitutions to different sets are given 
in the order just given and combined with a plus sign (hence “E50Q+D77N”, “D77N+E106Q”, and 
“E95Q/E97Q/D109N+E106Q”). Where this convention does not hold, substitutions are either 






 Co-assembly of hierarchically structured VLP–VLP and VLP–3.4.2.
TMV complexed nanorods  
 Neutralization of either axial or lateral of carboxylate interactions via bi-
directional axial substitutions E50Q+D77N or bi-directional lateral substitutions 
E95Q/E97Q/D109N+E106Q enhances intersubunit interactions and drives the self-
assembly of rod-like VLPs (Figure  3-1). However unidirectional carboxylate 
Figure 3-2: Models and TEM images of axially and laterally interacting carboxylates and substitutions. (A) 
Model of axially interacting carboxylates E50 and D77 present in wild-type TMV and TEM of wild-type TMV 
CP expressed in bacteria. (B) Model of neutralizing substitutions of axially interacting carboxylates E50Q and 
D77N and TEM of E50Q+D77N CP forming VLPs. (C) Model of neutralizing D77N substitution interacting with 
wild-type E50 and TEM of D77N CP forming bilayer disks. (D) Model of neutralizing E50Q substitution 
interacting with wild type D77 and TEM of E50Q CP forming VLPs. (E) Model of laterally interacting 
carboxylates E95, E97, and D109 interacting with neutralized E106Q substitution and TEM of D77N+E106Q CP 
combining this lateral substitution with the axial D77N substitution and forming VLPs. (F) Model of laterally 
interacting carboxylate E106 interacting with neutralized E95Q, E97Q, and D109N substitutions and TEM of 
E95Q/E97Q/D109N+E106Q CP combining these lateral substitutions with the axial E50Q and forming VLPs. 
Bars = 200 nm. 















neutralizations are also sufficient to drive VLP self-assembly, either through the 3ʹ-
end axial E50Q substitution (with or without the 3ʹ-end lateral E95Q/E97Q/D109N 
substitutions) or through the 5ʹ-end axial D77N combined with the 5ʹ-end lateral 
E106Q substitutions (Figure  3-2). Because the protein–protein interactions between 
the 3ʹ end of one TMV or VLP rod and the 5ʹ end of another is identical to those 
interactions between adjacent layers of the helix within an assembled rod, the 
potential for these assembly-promoting substitutions to selectively drive the “head-to-
tail” assembly of rods of distinct TMV CP variant type was investigated. To this end, 
the 5ʹ-end-neutralized D77N+E106Q mutant (Figure  3-3A, red) was labeled with a C-
terminal HA peptide while the 3ʹ-end-neutralized E50Q+E95Q/E97Q/D109N 
(Figure  3-3A, blue) mutant was labeled using a FLAG peptide. HA-labeled 
D77N+E50Q or FLAG-labeled E95Q/E97Q/D109N+E106Q was mixed with 
unlabeled TMV rods or bi-directional lateral-carboxylate-substituted 
E95Q/E97Q/D109N+E106Q, which retains wild-type axial carboxylates at both ends, 
(Figure  3-3A, green). Co-mixed samples were concentrated by centrifugation and 
resuspension at a ratio of 1:1 with respect to protein concentration. Results show the 
co-assembly of chimeric nanorods of varying lengths and relative composition, as 
verified by the selective immunolabelling of the FLAG- or HA-tagged CP with 
antibodies conjugated to gold nanoparticles and imaged by transmission electron 





 The efficiency of co-assembly, as determined by the average of the percentage 
of unlabelled rods attached lengthwise to a labelled rod and the percentage of labelled 
rods attached lengthwise to an unlabelled rod, was below 50% for all combinations of 
5ʹ-end-neutralized or 3ʹ-end-neutralized VLP with TMV or with bi-directionally 
laterally neutralized VLP, with 3ʹ-end-neutralized E50Q+E95Q/E97Q/D109N CP 
Figure 3-3: (A) Model showing schematic for selective-end-attachment of VLPs of modified CP to TMV (or VLP 
retaining wild-type axial carboxylates)(green, center). Neutrally charged residues (dark blue) substitued for 
negatively charged carboxylates (red) can be brought into proximity with wild-type carboxylates without 
generating destabilizing repulsion. E50Q+E95Q/E97Q/D109N VLP and CP (light blue, top) has neutralized 3ʹ-
end charges, allowing fusion to the 5ʹ end of TMV or a VLP with intact 5ʹ-end carboxylates. D77N+E106Q VLP 
and CP (light red, bottom) has neutralized 5ʹ-end charges, allowing fusion to the 3ʹ end of TMV. (B) TEM 
images of immunolabelled E50Q+E95Q/E97Q/D109N-FLAG VLP coassembled with unlabelled 
E95Q/E97Q/D109+E106Q VLP by concentrating an mixture of equal volumes of 1 mg/mL solutions of the two 
types of VLP in 0.01 M pH 7 sodium phosphate buffer through vacuum centrifugation to ~10% original sample 
volume, overnight incubation of the concentrated sample at 4 °C overnight, and dilution of the sample to the 
original volume with 0.1 M pH7 sodium phosphate buffer. Attachment success rate as defined by the average 
of the percentage of unlabelled VLP rods attached lengthwise to a labelled rod and the percentage of labelled 
VLP rods attached lengthwise to an unlabelled VLP rod was estimated to be ~40% based on the observation 
and counting of ~50 rods. (C) TEM images of immunolabelled D77N+E106Q-FLAG VLP coassembled with 
unlabelled TMV by ultracentrifugation of 100 μL each of 5 mg/mL solution of the two components diluted in 
0.1 M pH 7 sodium phosphate buffer and resuspension of the concentrated pellet in 100 μL 0.1 M pH 7 sodium 
phosphate buffer. Attachment success rate as defined by the average of the percentage of unlabelled TMV 
rods attached lengthwise to a labelled rod and the percentage of labelled VLP rods attached lengthwise to an 
unlabelled TMV rod was estimated to be ~10% based on observation and counting of ~50 rods.   Bars = 200 nm 
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showing the highest co-assembly efficiency with TMV at ~40% (Figure  3-3B) and 5ʹ-
end-neutralized D77N+E106Q CP showing co-assembly efficiency of ~10% 
(Figure  3-3C). The low attachment efficiency among all samples could be attributed 
to several factors. Some of these are methodological and could perhaps be improved 
by refining the conditions under which the rods are mixed. The first is the absolute 
concentration of the TMV and VLP components in the mixture were coassembly 
takes place. It is known that TMV assembly in host cells and E50Q/D77N VLP 
assemble in bacterial cells (Figure  2-2C) where the CP exists at high concentration. 
The ultracentrifugation and vacuum centrifugation steps used in the coassembly of 
these complexed rods were intended to provide similar increases in concentration to 
drive their coassembly, and repeating these steps may improve results. However the 
coassembly of these rods also requires the component rods to meet in the correct 
orientation of 5ʹ-rod-end to 3ʹ-rod-end. This positioning of the components in three-
dimensional space is presumably inhibited by the decreased mobility of the 
component rods compared to that of the monomers and disks that are involved in the 
do novo assembly of TMV and VLP rods. 
 The relatively lower efficiency of coassembly of the 5ʹ-neutralized rods 
(D77N+E106Q VLP) onto TMV rods when compared to the coassembly of 3ʹ-
neutralized rods (E50Q+E95Q/E97Q/D109N VLP) onto VLP retaining wild-type 
axial carboxylates (E95Q/E97Q/D109N+E106Q VLP) requires an additional 
explanation. This lower efficiency of coassembly is not necessarily the result of the 
use of TMV versus E95Q/E97Q/D109N+E106Q VLP or of the method used to 





centrifugation)_as these other components and methods were also evaluated and 
found to offer no improvement [data not shown]. Instead it may be attributable to an 
underlying structural asymmetry in the assembly process and as influenced by the 
axially interacting carboxylates. The evidence for this comes from two sources. First 
is the evidence in the extensive literature on the assembly process of the TMV virion 
which shows that elongation of the rod occurs primarily through different 
mechanisms at each end, with elongation of the 5ʹ rod end occurring rapidly by the 
addition of preassembled CP disks or “lock-washers” while elongation of the 3ʹ rod 
end occurs more slowly by the addition of monomers, dimers, trimers, etc. [200] 
Another indication of an underlying structural asymmetric affecting assembly is the 
observation, reported above, that while the E50Q mutation alone is sufficient to drive 
assembly of VLPs, the D77N mutation is not, which is consistent with previous 
studies of the effect of these mutations on virus in planta [96]. 
 
 Development of VLP CPs with novel end specific 3.4.3.
electrostatic interactions 
Initial studies showed the capability of both bidirectionally neutralized 
carboxylates as well as asymmetrically neutralized carboxylates to allow VLP 
nanorod assembly and a limited ability to co-assemble onto one end of TMV or a 
VLP retaining wild-type axially oriented carboxylates. To improve control over the 
efficiency and direction (from 5ʹ or 3ʹ rod ends) of multiple-particle co-assembly, the 
three-dimensional structure of the E50 – D77 carboxylate pair was modeled for the 





rotational space within the subunit interface at residue 77 to accommodate a lysine 
residue with its terminal amine group positioned within 3 Å of the opposing E50 
carboxyl group (Figure  3-4C). However, Structural models indicated the potential for 
repulsive electrostatic interference between a lysine substituted for residue E50 and 
residue R46 situated on the adjacent turn of an α-helix in the same subunit 
(Figure  3-5).  
Bacterial expression of C-terminally-peptide-tagged E50K CP and 
transmission electron microscopy of the bacterial lysate revealed the presence of 
micrometer-long loose sinusoidal or helical structures approximately 10 nm in 
diameter (Figure  3-5), which were interpreted as one-dimensionally aggregated E50K 
CP resulting from effects of the interaction between residues R46 and E50K. To 
eliminate the presumed electrostatic interference of R46 and to accommodate the 
E50K substitution an additional substitution of glycine for R46 was made, generating 
the R46G/E50K CP variant. Expression of this variant lacked the loose helical
Figure 3-4: Models and TEM imgaes of postively charged residues substituted for axially interacting 
carboxylates E50 and D77. (A) Model of two axially juxtaposed TMV CP subunits with axially interacting 
carboxylates E50 and D77 represented. (B) Ball-and-stick model of wild type, axially interacting carboxylates 
E50 (top) and D77 (bottom). (C) Ball-and-stick model of basic residue D77K interacting with E50. (D) Ball-and-
stick model of basic residue E50K interacting with D77. (F) TEM of wild-type TMV. (G) TEM of D77K VLP 
showing lengthened morphology. (H) TEM of R46G/E50K+E97G VLP showing lengthened morphology. Bars = 
200 nm 
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structures present in the E50K preparations but also indicated a poor ability to self-
assemble into tight helical TMV-like rods (Figure  3-5). To improve assembly stability 
and VLP formation, a targeted mutation (E97G) to the destabilizing group of laterally 
interacting carboxylates was made to produce the R46G/E50K+E97G CP variant. 
Both of these CP variants, D77K and R46G/E50K+E97G, were designed to 
introduce novel positive surface charges under neutral pH conditions to either the 5ʹ 
(D77K) or 3ʹ (R46G/E50K+E97G) CP interfaces. These positively charged D77K and 
E50K residues were expected to form salt-bridges with E50 or with D77, 
respectively, both between copies of identical modified CP, to drive assembly of 
homogeneous VLP, and between one end of the modified CP VLP and the opposite 
Figure 3-5: Models comparing wild-type TMV CP containing negatively charged axial carboxylates D77 and E50 
(green, top left) with E50K CP (blue, top) showing proximity of positively charged E50K to positively charged 
R46, R46G/E50K (blue, center) showing elimination of repulsive interaction between R46 and E50K by 
substituting a glycine for R46, R46G/E50K+E97G (blue, bottom) showing the additional substitution of a 
glycine for the laterally interacting carboxylate E97, and D77K CP (red, center left).  TEM images accompanying 
each model show E50K CP forming loose spirals instead of rods (top right), R46G/E50K showing poor VLP 
assembly (center right), R46G/E50K+E97G CP forming long VLP rods (bottom right), and D77K CP forming long 





end of wild-type TMV, to drive hierarchical co-assembly.  
When expressed in bacteria, both of these CP variants were found to generate 
VLP nanorods with extensively lengthened morphologies. Transmission electron 
microscopy revealed VLPs composed of either D77K or R46G/E50K+E97G CP to 
have typical lengths on the order of 1 µm or more (Figure  3-4G and H). This was 
consistent with the increased stability to rod assembly that was predicted to 
accompany the replacement of a negatively charged residue that would generate a 
repulsive axial interaction with not just a neutrally charged hydrophilic residue 
capable of generating an ion–dipole interaction but with a positively charged residue 
capable of forming a salt-bridge between adjacent subunits.  
In addition, each variant was found to undergo a unique disassembly response 
to different environmental conditions. Specifically, the D77K mutation disassembles 
at pH 9 while the wild-type TMV and VLP E50Q/D77N rods remain assembled 
under this elevated pH condition (Figure  3-6A). Additionally, restoring the 
disassembled D77K CP solution to pH 7 solution conditions results in the reassembly 
of the nanorods. Similarly, the R46G/E50K+E97G mutant CP also displays a unique 
disassembly behavior in response to a reduction of dissolved ion content of the 
ambient medium to submicromolar concentrations and a restoration of the assembled 
state with a subsequent increase in the ionic strength of the solution (Figure  3-7A). 
Interestingly, the conditions that trigger disassembly in each of these CP variants is 
not shared by the other: D77K VLP nanorods are primarily affected by pH and not by 
ionic strength while the R46G/E50K+E97G nanorods disassemble only at low ionic 






 Structural explanations for the unique disassembly behavior of the two 
modified CP variants must account not only for the unique disassembly response of 
each variant to solution conditions that do not produce the same effect in TMV or 
E50Q+D77N VLP but also the relative independence of disassembly response of each 
CP variant to the conditions that trigger disassembly in the other. Specifically, the 
mechanisms must explain the asymmetric responses of the two CP variants to pH and 
Figure 3-6: (A) TEM images of  TMV (top row), E50Q+D77N VLP (middle row), and D77K-HA CP samples 
dialyzed to pH 8 (left column), then to pH 9 (middle column), and finally pH 7 (right column) showing stability 
of TMV and E50Q+D77N VLP at all pH values, but total loss of visible structure for D77K-HA CP at pH 9. All 
samples prepared in 0.1 M Tris buffer. (B) SDS-PAGE of equal volumes of samples from A, above, showing no 





ionic strength conditions despite the similarity of the amino acid substitutions which 
produced them, namely, the substitution of the lysine for one or the other of the 
negatively charged, carboxylate-containing amino acid residues that interact axially. 
The proposed mechanism for the pH-based disassembly of D77K VLP, but 
not R46G/E50K+E97G, is the deprotonation and subsequent loss of positive charge 
of the lysine sidechain’s primary amine in alkaline conditions around pH 9. The pKa 
of this amine group in a dilute solution of free lysine is ~10.5. However, this value 
Figure 3-7: (A) TEM images of  TMV (top row), E50Q+D77N VLP (middle row), and R46G/E50K+E97G-FLAG CP 
(bottom row) samples dialyzed to high ionic strenght conditions (0.3 M NaCl, 0.1 M Tris) (left column), then to 
low solute, filtered water (middle column), and finally returning to high ionic strength conditions (0.3 M NaCl, 
0.1 M Tris) (right column) showing stability of TMV and E50Q+D77N VLP at all ion concentrations, but a 
general loss of structure for R46G/E50K+E97G-FLAG CP under very low ionic solute conditions (0 M NaCl). (B) 
SDS-PAGE of equal volumes of samples from A, above, showing little detectable sample loss during the 





can change considerably depending on the local microenvironment of the amine 
group in the folded protein and within the assembled rod. The proximity of other 
positive electrostatic charges creates energetically unfavorable conditions and 
effectively lowers the pKa of positively charged groups. The presence of a positively 
charge arginine, R46, in the vicinity of the lysine in D77K but not in 
R46G/E50K+E97G, where it was replaced with a glycine residue, may be sufficient 
to drive the deprotonation of D77K at pH 9 while the introduced lysine in 
R46G/E50K+E97G remains protonated and maintains its stabilizing axial salt bridge.  
However, while a differential lowering of the introduced lysine’s amine group 
may contribute to the two variants’ different pH stability profiles, it is in itself neither 
necessary to explain the stability of R46G/E50K+E97G at pH 9 nor sufficient to 
explain the dramatic instability of D77K under the same conditions, Even allowing 
Figure 3-8: TEM images showing relative independence of disassembly conditions for the D77K and 
R46G/E50K+E97G CP variants. Both variants exist in an assembled state as elongated VLP rods after dialysis in  
0.1 M pH 7 Tris (center images). After dialysis with filtered water (adjusted to pH 7 with ~50 μL NaOH /  1 L 
H2O), D77K CP shows retention of assembled VLP structure (top left), while R46G/E50K+E97G shows significant 
loss of assembly structure (bottom left). Alternatively, dialysis of the samples from 0.1 M pH 7 Tris (center 
column) to pH 9 (right column) triggers the complete loss of virus-like particle structure in D77K CP (top right), 
while R46G/E50K+E97G CP retains its assembly structure. [Note: R46G/E50K+E97G samples dialyzed with 0.1 
M pH 7 Tris (bottom center) and 0.1 M pH 9 Tris (bottom right) exhibit an apparently weakened, more 





the possibility that the pKa of the lysine’s amine group is sufficiently lowered in both 
variants to drive its respective deprotonation at pH 9, eliminating the stabilizing 
intersubunit axial salt bridge, structural considerations suggest that the substitution of 
the larger side chain volume of the substituted lysine residue for the smaller aspartic 
acid residue D77 would introduce a significant instability in the form of steric 
interference at the CP interface when deprotonated, resulting in the rapid 
destabilization of the TMV nanorod. In contrast, substitution of lysine for the slightly 
larger glutamic acid E50 within the assembled R46G/E50K+E97G rod would 
introduce less steric intersubunit interference, which may be further accommodated 
by the substation of a much smaller glycine for the bulky arginine R46 in that same 
variant adjacent to the lysine. Finally, even allowing for the deprotonation of the 
introduced lysine in both variants at pH 9 and the possibility that the difference in 
behavior is not due to a differential introduction of steric interference by the lysine, 
the behavior of the two variants is remarkably similar to the asymmetrical assembly 
behavior of the D77N and the E50Q CP variants, in which substitution of an 
uncharged amino acid residue for one of the axially interacting carboxylates acid does 
not generate self-assembly behavior for substitution of D77 but does for substitution 
of E50.    
For the ionic strength-based disassembly of R46G/E50K+E97G but not 
D77K, structural modeling of suggests that the predicted assembly-promoting salt-
bridge between the introduced lysine and the axially oriented carboxylate on the 
opposing subunit could be supplementally stabilized by dissolved ions. While the side 





interacting with D77 on the opposing subunit, the E50K lysine is also positioned to 
interact with R71 of the opposing subunit, generating a repulsive interaction. This 
repulsive interaction may be mitigated by an ion screening effect when sufficient 
negative ions are present, allowing the ionic strength of the solution to control the 
assembly of this nanorod. The D77K lysine, however, does not interact across an 
intersubunit boundary with R71, and so VLP assembly would not be expected to 
depend on dissolved ions for charge screening. 
Thus, these two mutations create distinct and orthogonal disassembly triggers, 
allowing the use of either pH or ionic strength as drivers in nanorod assembly and 
disassembly, making them ideal for controlling the assembly of chimeric VLPs. 
 Assembly kinetics 3.4.4.
The kinetics of the environmentally dependent assembly of the CP variants 
D77K and R45G/E50K+E97G was investigated by measuring changes to the light 
scattering of solutions of CP after a sudden change in pH or ion concentration that 
initiates the transition from a disassembled state to an assembled one. A fluorescence 
spectrophotometer was used to measure the scattering of a sample of either (1) 25 μL 
of disassembled D77K-HA CP in a 0.1 M pH 9 Tris solution which was then diluted 
eight-fold with 175 μL of 0.1 M pH 5 Tris or else (2) 100 μL  of R46G/E50K+E97G -
FLAG CP in filtered, low ion content pH 7 water which was then mixed with an 
equal volume (100 μL) of 0.2 M Tris 0.6 M NaCl to achieve final solution conditions 
of ~ pH 7 or 0.1 M Tris 0.3 M NaCl, respectively. Samples were illuminated with 
monochromatic 340 nm wavelength light, and a detector located at 90° to the incident 





determine the assembly state of the CP in the sample. Three samples at each of three 
concentrations for each of the two CP variants were measured for real time assembly 
state. Because the absolute amount of light scattering was dependent not only on the 
assembly state of the CP in the sample but also the total CP concentration and the 
intensity of the incident light (which needed to be varied between the most and least 
concentrated samples to achieve adequate light scattering for each sample without 
oversaturating the detector), the scattering profile for each sample concentration was 
normalized to a measurement of the scattering at a much later time (t>2hours) when 
the sample was assumed to have reached a state of maximum assembly relative to the 
CP concentration. The results (Figure  3-10, Figure  3-11, Figure  3-13, and 
Figure  3-14) were generally consistent with expectations that the light scattering 
curves would follow a rapid initial increase corresponding to the rapid association of 
CP monomers or oligomers into rods due to the high availability of free CP followed 
by a gradual flattening as the concentration of dissociated CP decreased as well as the 
expectation that initial assembly rate would correlate positively with initial CP 
concentration.  
For pH-based D77K reassembly, the light scattering measurements closely 
followed the expected pattern (Figure  3-11). Very low initial scattering values were 
consistent with electron microscope imaging data that reliably showed no discernible 







Figure 3-9 Normalized 90° light scattering curves correlating to reassembly of D77K CP from initial 
disassembled state after dialysis pH 9 Tris buffer with sudden adjustment to pH 7 by the 8-fold dilution with 
pH 5 Tris buffer at t=0. Samples were measured two or three times for final D77K-HA  concentrations (after 
addition of pH 5 Tris) of 1 mg/mL (red), 0.5 mg/mL (green), and 0.25 mg/ml (blue). All curves were normalized 
relative to amount of scattering for the sample after >2hours, when it is assumed to have reached maximum 






Table 3: Assembly values derived from 90° light scattering measurements of D77K-HA CP. Averaged initial 
assembly rate values are averages over the first minute of assembly. 
pH-based D77K-HA CP Assembly Parameters 




Average initial assembly rate 
(%/sec) 
0.25 mg/mL 24 46.9 0.055 
0.5 mg/mL 2.4 18.2 0.49 
1 mg/mL 0.95 9.5 0.82 
Figure 3-10: Averaged normalized 90° light scattering curves correlating to reassembly of D77K CP from initial 
disassembled state after dialysis pH 9 Tris buffer with sudden adjustment to pH 7 by the 8-fold dilution with 
pH 5 Tris buffer at t=0. Samples were measured two or three times (averaged curve shown) for D77K at 
concentrations of 1 mg/mL (red), 0.5 mg/mL (green), and 0.25 mg/ml (blue). All curves were normalized 
relative to amount of scattering for the sample after >2hours, when it is assumed to have reached maximum 





For ionic-strength-based R46G/E50K+E97G reassembly, there were two notable 
deviations from the expected saturation curve (Figure  3-9). First, the initial light 
scattering values were significantly higher than for the D77K samples. This is 
consistent with the observation of some persistent intersubunit associations among 
R46G/E50K+E97G CP even in very low ionic strength conditions. In addition, the 
curves for the 0.6 mg/mL and 0.3 mg/mL samples appear to show a marked levelling 
off or lag phase after a rapid increase in light scattering to around 80% maximum. 
This lag phase is followed by a second relatively rapid increase in scattering to near 
100% before again flattening. The mechanism behind this apparent two-phase process 
is unknown.  
 
Figure 3-11: Plot of pH-based reassembly rate of D77K-HA CP versus time at three different concentrations, 
showing concentration dependence or rate. The y-value of each line at any point corresponds to the slope of 















Figure 3-12 Normalized 90° light scattering curves indicating reassembly of R46G/E50K+E97G CP from initial 
disassembled state after dialysis with very low salinity pH 7 water after sudden adjustment to 0.1 M Tris, 0.3 
M NaCl, pH 7 by 2-fold dilution with 0.2 M Tris, 0.6 M NaCl, pH 7 . Samples were measured three times for 
final R46G/E50K+E97G concentrations (after 2-fold dilution) of 0.6 mg/mL (red), 0.3 mg/mL (green), and 0.15 
mg/ml (blue). All curves were normalized relative to amount of scattering for the sample after >2hours, when 






Ion-based R46G/E50K+E97G-FLAG CP Assembly Parameters 




Average initial assembly rate 
(%/sec) 
0.15 mg/mL 16.8 61 0.08 
0.3 mg/mL 2.0 26 0.31 
0.6 mg/mL 0.14 4.7 0.58 
Table 4:  Assembly values derived from 90° light scattering measurements of R46G/E50K+E97G-FLAG CP. 
Averaged initial assembly rate values are averages over the first minute of assembly. 
 
Figure 3-13: Averaged normalized 90° light scattering curves indicating reassembly of R46G/E50K+E97G CP 
from initial disassembled state after dialysis with very low salinity pH 7 water after sudden adjustment to 0.1 
M Tris, 0.3 M NaCl, pH 7. Samples were measured three times (averaged curve shown) for R46G/E50K+E97G at 
concentrations of 0.6 mg/mL (red), 0.3 mg/mL (green), and 0.15 mg/ml (blue). All curves were normalized 
relative to amount of scattering for the sample after >2hours, when it is assumed to have reached maximum 






 End-directed assembly of VLP subunits through novel 3.4.5.
electrostatic interactions 
The unique pH and ionic strength assembly profiles of D77K and 
R46G/E50K+E97G, respectively, were investigated as a means to direct CP assembly 
onto TMV at either the 3ʹ end (for D77K) or the 5ʹ end (for R46G/E50K+E97G). 
While the amino acid substitutions to these CPs were expected to guide this 
directional assembly onto TMV, the extensively lengthened morphology of the VLPs 
they form hinders the co-assembly process. However the unique disassembly–
reassembly behavior of these particles provides a method for eliminating the 
homogeneous structure of the long rods and enables their recombination with the 
Figure 3-14: Plot of ionic strength-based reassembly rate of R46G/E50K+E97G-FLAG CP versus time at three 
different concentrations, showing concentration dependence or rate. The y-value of each line at any point 





TMV particles. For these experiments the 5ʹ-end-substituted D77K mutant was 
labeled with a C-terminal HA peptide tag while the 3ʹ-end-substituted 
R46G/E50K+E97G mutant was labeled using a FLAG peptide tag. Solutions 
containing unlabeled TMV and modified CP VLPs were combined and dialyzed 
against solution conditions to cause disassembly of the modified CP VLPs. For 
D77K-HA VLP, this entailed dialysis to pH 9 (Figure  3-10B), for 
R46G/E50K+E97G, dialysis to filtered water adjusted to pH 7 (Figure  3-10A). Buffer 
conditions for these mixtures were then adjusted back to pH 7 or increased salinity 
(300mM NaCl) by dialysis to initiate reassembly of the D77K or R46G/E50K+E97G 
CP, respectively. Samples were then immunolabelled with anti-FLAG or anti-HA 
antibodies and imaged by TEM.  
Results from attempts with D77K-HA CP clearly show consistent and efficient 
Figure 3-15: Illustrative, schematic models and TEM of pH- and ionic strength-based disassembly–reassembly 
mechanism for hierarchical assembly of VLP-TMV complexed rods. (A) Ionic strength-based disassembly and 
reassembly of R46G/E50K+E97G CP onto TMV. (B) pH-based disassembly and reassembly of D77K CP onto 
TMV. (C) Schematic of differential immunolabelling of protein tagged CP with anti-tag antibodies. (D) TEM of 
D77K-HA CP co-assembled onto a TMV rod  with anti-HA-tag immunolabelling of the D77K CP. 









co-assembly of D77K-HA CP onto one end of the unlabelled TMV (Figure  3-11A). 
The resulting hybrid unlabeled TMV – D77K-HA VLP nanorods had a high degree of 
uniformity of length and were cleanly segregated into unlabeled and labelled sections 
by the anti-HA antibodies. The relative uniformity of length raised concern that the 
TMV’s RNA genome was playing a structural role in the coassembly of the D77K-
HA CP. The mechanism of TMV infection of a host cell is known to involve the 
exposure of the RNA 5ʹ end by selective disassembly at that rod end due to increased 
pH level upon entry into the cell interior. To test whether the D77K-HA CP was 
reassembling around the TMV RNA exposed by partial disassembly of the rod during 
dialysis to pH 9, RNase A was added to the combined TMV and VLP sample after 
dialysis to pH 9. Samples were they dialyzed back to pH 7, immunolabelled and 
imaged. The resulting hybrid nanoparticles displayed a broader distribution of lengths 
than samples not treated with RNase A with lengths exceeding those expected if the 






 Coassembly of R46G/E50K+E97G-FLAG CP onto TMV by the depletion and 
subsequent replenishment of dissolved ions also showed positive results. Samples 
taken from the low ionic strength conditions appeared to show coassembly of TMV 
D77K VLP pH-based assembly onto 3’ end 
Figure 3-16: TEM images of longitudinally ordered TMV–VLP hybrid nanorods resulting from pH-based VLP 
disassembly/reassembly. All samples were prepared by the 2:1 mixture of 5 mg/mL solutions of D77K-HA VLP 
and TMV in 0.1 M pH7 Tris buffer, dialysis against a pH 9 solution of 0.1 M Tris buffer overnight at 4 °C, and 
then dialysis back to pH 7 with 0.1 M Tris buffer overnight at 4 °C. (A) and (B) Immunolabelled D77K-HA CP 
extending the lengths of unlabeled TMV with no RNase treatment. (C) Immunolabelled D77K-HA CP extending 
the lengths of unlabeled TMV treated with RNase (0.5 μL / 50 μL solution) for 30 minutes at 37 °C  after 





with the R46G/E50K+E97G-FLAG CP, but with the R46G/E50K+E97G-FLAG CP 
exhibiting the loose and fragmented structure evident from previous samples dialyzed 
to low ionic strength conditions (Figure  3-12, left side). The reintroduction of ions by 
addition of an equal volume of 0.4 M NaCl resulted in stabilization of the modified 
CP (Figure  3-12, right side). In contrast to the hybrid nanoparticles created using 
D77K CP, R46G/E50K+E97G–TMV hybrid nanoparticles mainly retained the 




Figure 3-17: TEM images of longitudinally ordered TMV–VLP hybrid nanorods resulting from ionic-strength-
based VLP disassembly/reassembly.  Immunolabelled but unstructured R46G/E50K+E97G-FLAG CP extending 
the lengths of unlabeled TMV in low ionic strength conditions (left).  Immunolabelled and well-structured 





 Surface-bound fabrication of co-assembled nanoparticles 3.4.6.
 To investigate the potential for integration of longitudinally differentiated 
protein nanoparticles into functional devices by surface attachment via the 1cys 
mutation (the addition of a cysteine residue proximal to the N-terminus), attempts 
were made to “grow” coassembled nanoparticles by sequential deposition of 
components onto a gold-coated silicon substrate. The gold surfaces were incubated in 
buffer with or without TMV-1cys, which is well established to attach itself to gold. A 
substantial number of TMV particles attach in an orientation perpendicular to the 
surface with what is thought to be the 3ʹ virion end serving as the point of attachment, 
based on molecular models. The surfaces were washed and incubated with a blocking 
solution. They were then washed briefly in filtered water and a small volume of 
R46G/E50K+E97G-FLAG CP disassembled by ion depletion was deposited on the 
surface. R46G/E50K+E97G-FLAG CP reassembly was initiated with the introduction 
of concentrated salt solution. The chips were then washed and immunolabelled with 
horseradish peroxidase-conjugated antibodies to visualize the presence of FLAG-
tagged CP via color change (Figure  3-13B). Because R46G/E50K+E97G-FLAG CP 
lacks surface cysteine residues, it is assumed that its presence on the chip will either 
be due to non-specific adsorption or through interactions with a substrate layer of 
TMV-1cys (Figure  3-13A). Results indicate a correlation between the initial 
deposition of TMV-1cys and retention of FLAG-tagged CP, consistent with the 
hierarchical co-assembly of R46G/E50K+E97G-FLAG onto the surface-distal 5ʹ end 






Figure 3-18: (A) Schematic of surface-bound “growth” of coassembled hybrid nanoparticles with D77K or 
R46G/E50K+E97G VLP only attaching to the gold surface through coassembly on a TMV-1cys intermediary base 
layer. (B) Results of TMV-1cys and R46G/E50K+E97G-FLAG CP surface-bound coassembly, in which TMV-1cys 
was first deposited on to gold-coated silica wafers followed by disassembled R46G/E50K+E97G-FLAG CP in 
water, followed by an equal amount of Tris with salt for a final concentration of 0.3 M NaCl, 0.1 M pH 7 Tris to 
initiate reassembly of the CP onto the free ends of the surface bound TMV. The presence of FLAG-tag labelled 
R46G/E50K+E97G CP was evaluated by colorimtric change catalyzed by alkaline phosphatase conjugated to 
antibodies targeting the FLAG-tag. (C) Results of TMV-1cys and D77K-HA CP surface-bound coassembly, in 
which TMV-1cys was first deposited on to gold-coated silica wafers followed by disassembled D77K-HA CP in 
water, followed by an 7-fold addition of pH 5 Tris for a final pH of 7 to initiate reassembly of the CP onto the 
free ends of the surface bound TMV. The presence of HA-tag labelled D77K CP was evaluated by colorimtric 
change catalyzed by alkaline phosphatase conjugated to antibodies targeting the HA-tag. 




   
 





 Similar results, however, were obtained with similar experiments using the 
pH-based disassembly and then surface-attachment reassembly of D77K-HA CP. 
Surfaces incubated first with the highest concentration of TMV-1cys before having 
disassembled D77K-HA CP deposited and reassembled by the addition of low pH 
buffer gave the strongest indication of retained HA-tagged CP. Samples negative for 
initial TMV-1cys deposition or D77K-HA CP addition gave weak color change 
responses. This is consistent with the longitudinal coassembly of D77K-HA CP with 
TMV-1cys but not consistent with models of the orientation of surface-bound TMV-
1cys and models of the orientation of attachment of D77K CP to TMV. According to 
these models, D77K CP should compete for attachment to the 3ʹ end of TMV-1cys 
with the gold surface. 
 Conclusion 3.5.
In this work, knowledge of the native structure and mechanism by which TMV 
regulates virion assembly was used to engineer a novel system for the generation of 
hierarchically assembled, complex nanoparticles. TMV capsid protein has several 
surface-exposed residues with carboxylate-containing sidechains. In the assembled 
virion, where many copies of the capsid protein are stacked in a repeating helical 
pattern, these residues are placed in close proximity to others on the neighboring 
copies of the capsid protein. Throughout the typical infection and reproduction cycle 
of the virus the ambient environmental pH and ionic conditions outside the host 
system can serve to moderate the destabilizing interaction between juxtaposed 
carboxylates, while inside a host cell environmental conditions allow the repulsive 





carboxylate-containing residues involved in this process are the glutamic acid E50 
and the aspartic acid D77, which interact between CP oriented along the virion axis. 
Previous work had established that neutralization of both of these residues by 
substitution with the similarly sized but neutrally charged glutamine (E50Q) and 
asparagine (D77N) produced a CP which would assemble into RNA-free virus-like 
particles at neutral pH. Here, it was shown that E50Q alone is sufficient to drive this 
assembly, while D77N alone is not. Additionally, the neutralization of a second set of 
carboxylate containing residue, E106 with E95/E97/D109, between laterally adjacent 
CP subunits, will also generate VLP, and the combination of the lateral E106Q 
substitution with the non-assembling D77N substitution can restore VLP-forming 
assembly behavior. It was also shown that the destabilizing axial interaction can be 
replaced by a stabilizing interaction between a positively charged and a negatively 
charged residue by substitution of a lysine (K) for either E50 or D77, producing 
supermicrometer length VLPs that uniquely disassembly under low ionic strength or 
low pH solution conditions, respectively. Finally, it was shown that the unique 
combination of negative, neutral, or positive charges at the 5ʹ and 3ʹ ends of each of 
the VLPs formed by these CP variants can be used to selectively direct the head-to-
tail assembly of TMV with VLP containing compatible or complementary end 
charges. In the case of single-end-neutralized VLPs D77N+E106Q and 
E50Q+E95Q/E97Q/D109N, results showed that this coassembly occurred with low 
efficiency, but that the unique pH- or ionic strength-based disassembly and 
reassembly behavior of the lysine substituted mutants D77K and R46G/E50K+E97G 





efficient and reproducible manner to generate hybrid nanoparticles with different 
functional capabilities distributed in discrete, well-ordered sections along the 






Chapter 4: Conclusion 
 Summary of Research and Accomplishments 4.1.
 In this dissertation research, a system of modifications to Tobacco mosaic 
virus (TMV) capsid protein (CP) was developed to explore the mechanisms 
underlying the assembly behavior of these naturally occurring nanoparticles and to 
selectively generate novel nanoparticles with alternative functional morphologies and 
complex architectures. Initially building on previous research into TMV assembly, 
targeted changes to the amino acid sequence of the CP gene through genetic 
modification successfully resulted in the first reported self-assembling TMV virus-
like particles (VLPs). Further modifications to alter the directionality and strength of 
intermolecular CP–CP interactions resulted in the successful development of library 
of CP variants that self-assemble into VLPs with alternative functional morphologies, 
with unique electrostatic surface charge profiles, and with either broad environmental 
stabilities or with dynamic, environmentally sensitive disassembly and reassembly 
behavior. Finally it was shown that the unique properties and behaviors of these 
novel, alternative VLP-forming CPs can be exploited to drive higher-order assembly 
behaviors to generate TMV-based nanoparticles with another dimension of structural 
complexity. This resulted in the successful creation of hybrid VLP–TMV 
nanoparticles with longitudinally ordered and differentiable function. 
  Technological innovation at the nanometer scale has the potential to confer 
significant improvements to a wide range of applications, and Tobacco mosaic virus 





of functional nanomaterials. However, TMV as a platform for functional nanoscale 
materials had several limitations including long production times, the high risk of loss 
of engineered function through genetic recombination, and a structurally based 
homogeneity of function along the length of the nanoparticle. 
 Initial efforts sought to alleviate these limitations through the creation of 
TMV virus-like particles (VLPs). Based on the knowledge that TMV CP contained 
several negatively charged, carboxylate containing residues (aspartic acid (“D”) and 
glutamic acid (“E”)) that interacted repulsively between adjacent copies of the CP 
within the assembled rod to moderate its structural stability, a CP variant with two 
neutralizing substitutions (E50Q and D77N) was expressed in bacteria to create the 
first RNA-free, TMV VLP composed of protein alone. This VLP was characterized, 
and found to be nearly indistinguishable from TMV in terms of stability across a 
range of pH conditions and function. These particles can be functionalized by the 
extension of the N- or C-terminus with peptide chains for analyte target binding, 
epitope display or bioconjugation sites with less concern for loss of function due to 
genetic reversion. Addition of the N-terminal 1cys mutation enabled its vertically 
oriented attachment to surfaces for device integration and metallization via electroless 
plating for high-surface area electrodes. The primary notable difference from TMV 
was the broader distribution of particle lengths due to the lack of length-determining 
RNA. 
 Based on this initial success, a library of modified TMV CP variants were 
created which differentially altered the two known sets of carboxylates that interacted 





which interacts in an axial direction with 3ʹ-end-oriented E50 and (ii) the 5ʹ-end-
exposed E106 which interacts laterally with the 3ʹ-end-exposed E95/E97/D109 
cluster. The modifications were made to investigate the effects of eliminating these 
repulsive interactions – through substitutions of neutral residues for the negatively 
charged carboxylate residues versus creating attractive interactions by substituting 
positively charged residues – and to investigate how the direction of these new 
interactions affected assembly – by comparing substitution of one member of a set of 
interacting carboxylate pair to substitution of the other member(s) of the pair. It was 
found that neutralizing one member of the axially interacting carboxylate pair (E50Q) 
but not the other (D77N) was sufficient to drive VLP assembly. It was found that 
neutralization of the laterally interacting carboxylate group 
(E95Q/E97Q/D109N+E106Q) without altering the axially interacting pair was also 
sufficient to drive assembly and that the addition of the laterally-interacting 
substitution E106Q to the nonassembling D77N substitution was sufficient to drive 
VLP-assembly. Finally, it was found that the positively charged axial carboxylate 
substitutions D77K and E50K (with compensatory R46G and E97G substitutions) 
further stabilized macromolecular assembly, generating very long VLP particles that 
exhibited unique and reversible disassembly behavior under conditions of high pH 
and low ionic strength, respectively. 
 This set of independently assembling VLP constructs differed from one 
another in the distribution of electrostatic charges at the two separate VLP rod ends. 
Whereas the wild-type TMV virion has negative charges which are brought into 





generating a net repulsive interaction and inhibiting fusion of the two particles into a 
single large rod, the newly created VLP rods were engineered to display various 
combinations of electrostatic charge profiles at the two rod ends. These included 
negative (E50), neutral (E50Q), or positive (E50K) charged residues exposed at the 3ʹ 
end of the VLP and negative charge (D77), neutral (D77N), or positive (D77K) 
charged residues at the 5ʹ end.  
 The last part of this research focused on using this engineered feature of the 
newly created VLP-producing CP to investigate the potential for the directionally 
specific coassembly of heterogeneous CP types into single particles with 
longitudinally separable functions. While the use of the end-charge-neutralized VLP 
containing E50Q or D77N were found to have inefficient coassembly capabilities 
with TMV, the lysine substituted variants containing E50K or D77K were predicted 
to perform better based on modelling and assembly data for these variants in 
isolation. The unique disassembly behavior of these VLP-forming variants was 
exploited to develop methods to direct the reassembly of these component CP 
subunits onto one end of TMV in an efficient and reproducible manner. This resulted 
in the development of an assembly system capable of generating hierarchically 
structured nanorods with longitudinally differentiable functional capabilities that can 
be integrated into devices via surface attachment for advancing a range of 
applications that would benefit from the improvement of structural control over 






 Challenges and Future Directions 4.2.
 This dissertation research presents a new system for the fabrication of 
nanoparticles with unique and complex assembly behaviors and architectures. 
However some challenges need to be overcome before the potential for this system is 
fully realized. These include control of particle lengths of VLPs and of components of 
longitudinally ordered TMV+VLP or VLP+VLP complexes, understanding particle 
stability with respect to the significance of dynamic equilibrium and of the role that 
divalent cations may play, and establishment of methods for longitudinally ordered 
double end assembly. Double end assembly to create well-ordered, longitudinally 
differentiable, three component nanoparticles is theoretically feasible, but has not yet 
been shown, and the system would be improved by methods to achieve the more 
complete disassembly of the R46G/E50K+E97G CP VLP, whose incomplete 
disassembly currently limits the ability to limit the length of the coassembled 
nanoparticles produced using this CP variant as a component. 
 The current work establishing the components and methods for fabrication of 
longitudinally ordered nanoparticle complexes emerged from the earlier successes in 
manipulating intersubunit interactions for the purposes of moving from the use of 
TMV as a functionalizable nanoparticle platform requiring plant-based fabrication to 
a VLP-based platform with all the advantages that platform provides. However, the 
fabrication of the nanoparticle complexes detailed in this dissertation has still 
incorporated TMV as a component of those complexes. To fully realize the 
advantages of VLPs as an alternative to a plant-based virus platform, it is envisioned 





However, attempts to replicate successes in the fabrication of longitudinally ordered 
TMV+VLP complexed nanoparticles without TMV and using only VLP and CP 
components have generated less robust and more inconsistent results. These attempts 
have generally entailed replacing the RNA-containing TMV component of the 
complexed nanoparticle with the RNA-free E95Q/E97Q/D109N+E106Q VLP. This 
VLP, in which all and only the laterally interacting carboxylate containing residues 
have be substituted with analogous residues with uncharged hydrophilic sidechains, 
was viewed as a plausible substitute for TMV due to its retention of the axially 
oriented carboxylates E50 and D77, which were understood to play a more important 
role in the longitudinal coassembly of multiple nanorod components. The problems 
encountered in these attempts to replace TMV with E95Q/E97Q/D109N+E106Q VLP 
point to some of the difficulties and challenges that will need to be overcome to move 
to a fully virus-free protein-based system platform. 
 First, the relative lack of control over the length of the assembled particles in 
VLP when compared to TMV is compounded when attempting to combine various 
VLPs in a longitudinally discrete and well-ordered manner. The RNA genome 
encapsidated by TMV provides a well-established method for controlling the length 
of the viral nanoparticles. In the fabrication of TMV+VLP complexes, the RNA 
scaffold can not only be used to control the length of the TMV portion of the 
longitudinally ordered TMV+VLP complex, but it could also provide a mechanism 
for control of the length of the VLP portion of the complex. The mechanism detailed 
in this work, which uses solution conditions to trigger the disassembly and 





D77K and R46G/E50K+E97G, is thought to proceed either by the use of one end of 
the TMV as a nucleation point for the addition of disassembled monomers directly or 
else as a point of attachment for disks or short barrels of the modified CP after they 
have formed in solution. Which of these mechanisms occurs has not yet been 
determined and may depend on which end of the TMV rod is being extended. It is 
plausible in theory, although it has not yet been shown in practice, that the relative 
abundance of TMV and modified CP could be used to provide some control over the 
length of the VLP portion of the complexed nanoparticle as process goes to 
completion and the disassembled CP is depleted from solution. When 
E95Q/E97Q/D109N+E106Q VLP is substituted for TMV, though, the relationship 
between the relative abundance of E95Q/E97Q/D109N+E106Q CP in solution and 
the number of VLP rod ends it supplies as nucleation points for the assembly of 
D77K or R46G/E50K+E97G is no longer tightly constrained. This uncertainty would 
be expected to be carried over into an additional lack of control over the length of the 
D77K or R46G/E50K+E97G portion of the complexed nanoparticle. 
 Another significant challenge that may be caused by the lack of an RNA 
scaffold, which may help explain the inconsistent results obtained so far using RNA-
free components, is the role that RNA may play in maintaining a static equilibrium 
with respect to assembled particle stability, as opposed to a dynamic equilibrium. 
While the RNA scaffold of TMV and the strengthened intersubunit attraction 
afforded by the introduction of salt bridge-like interactions in elongated VLP 
composed of the lysine-substituted variants D77K and R46G/E50K+E97G provide 





that shorter VLP with weaker intersubunit interactions are in a state of constant flux, 
with monomers or disks disassembling from one end and reassembling on the other as 
well as longer rods fracturing and shorter rods fusing. This could negatively impact 
the stability of complexed nanoparticles with these VLP as components, as the VLP 
which provide their rod ends as nucleation points for the directed assembly of other 
VLP components subsequently fracture or disassemble and reassemble as non-
complexed VLP. 
 The use of only virus-like particle components, without included virus 
components, has some clear advantages, and yet particle stability and control over the 
length distribution of the component segments of the hybrid nanorods, as well as their 
total length, are necessary for their functionality in diverse applications, including the 
study and use of spatial arrangement and segregation of enzymatic cascade 
components for energy harvesting, sensing, or chemical fabrication purposes. Several 
options are available. One potential solution is the use nongenomic RNA to act as a 
scaffold for the support of bacterially expressed CP to provide length control and 
particle stability as referenced in the introductory chapter of this dissertation [90-93]. 
This method for controlling and stabilizing individual particles could be combined 
with the methods developed here to guide interactions between particles and to 
fabricate well-ordered and stable nanoparticle complexes. An additional method 
which is currently being explored to control length and may be effective for many 
purposes is the use of microfluidics to progressively “grow” these nanoparticles on a 





 Another important factor that this work does not address is the use of divalent 
cations such as Ca++ as a stabilizing agent for VLP assembly. The presence of 
calcium ions in the extracellular environment is known to stabilize the TMV rod by 
mitigating the destabilizing effects of the intersubunit carboxylate interactions. The 
moderated addition of Ca++ in controlled amounts could provide a simple and 























 TMV coat protein expression constructs 4.2.1.
 The TMV coat protein open reading frame (ORF) carrying the E50Q and 
D77N modifications was codon optimized for expression in E. coli (GenScript, 
Piscataway NJ: Supplemental Fig. 1) and inserted into the pET-21a(+) expression 
vector (Novagen, Madison WI) via NdeI and XhoI restriction sites. Further 
modifications to the N- and C-terminus of the coat protein ORF were achieved by 
primer based PCR mutagenesis using oligonucleotides containing additional or 
altered sequences (Table 1). A cysteine codon was added at position two at the N-
terminus of the coat protein ORF to produce TMV-VLP1cys for enhanced metal 
coatings and oriented surface-binding [162]. Sequences encoding the binding peptides 
for FLAG epitope (DYKDDDDK) were added to the coat protein C-terminus [163]. 
Sequences binding the fluorescent imaging agent GenhanceTM 680 (IQSPHFF) were 
added to the coat protein C-terminus as fusions either with or without preceding 
sequences encoding a “leaky” amber stop codon (TAG) or a flexible 10 amino acid 
linker (GGGGSGGGGS) [164], [165]. Amplified PCR products containing 5ʹ NdeI 
and 3ʹ XhoI restriction sites were used to ligate the modified coat protein ORFs into 
similarly cut pET-21a(+) vector. 
 Induction and purification of TMV-VLPs 4.2.2.
 Coat protein expression constructs were transformed into BL21 competent E. 





containing the amber stop codon TAG. JM109 cells carry the supE44 suppressor of 
the amber stop codon via a tRNA mutation that transitions the GUC glutamine 
anticodon to AUC [166]. Transformed cells were cultured at 37oC in LB broth 
containing ampicillin (100 μg/ml) / chloramphenicol (50 μg/ml) for BL21 and 
ampicillin (100 μg/ml) / nalidixic acid (30 μg/ml) for JM109 cells to an OD600 of 0.5. 
Cells were then induced by the addition of 0.1 mM IPTG and incubated overnight at 
25°C. Induced cells were harvested by centrifugation at 4°C and lysed using 
BugbusterTM with LysonaseTM according to the manufacturer’s protocol (Novagen, 
Madison WI). Dithiothreitol to a concentration of 0.5 mM was added to the cell 
lysates followed by 3-5 min of sonication in a Branson 1510 sonicator (Branson 
Ultrasonics, Danbury CT). One third volume of chloroform was then added to the 
lysates, mixed and separated by centrifugation for 10 min at 17,000 × g at 4°C. 
Because of the hydrophobic nature of the IQ peptide the chloroform purification step 
was replaced by centrifugation at 800 × g for 1 min, centrifugation of the resulting 
supernatant at 66,400 × g for 30 min, and resuspension of the pellet in 3 mL of 0.1 M 
pH 7 sodium phosphate buffer. VLPs were then precipitated by the per volume 
addition of 1.5% KCl and 6% polyethylene glycol for one hour at 4°C. VLPs were 
then pelleted by centrifugation for 10 min at 17,000 × g. The resulting pellet was 
resuspended by shaking overnight in 0.5 to 2 mls of 0.1 M pH 7 sodium phosphate 
buffer. Resuspended VLP pellets were then loaded onto a 10 to 40% sucrose gradient 
in 0.1 M pH 7.0 sodium phosphate buffer and centrifuged for 1 hr at 91,000 × g at 





concentrated by centrifugation for 1 hr at 92,000 × g at 4°C. The purified VLP pellet 
was then resuspended in 0.1 M pH 7 sodium phosphate buffer.  
To visualize VLPs within bacteria, cells were induced overnight and 
subsequently prepared by pelleting, followed by fixing in 2% gluteraldehyde in 
phosphate buffered saline (PBS) with 0.29 M sucrose. Post-fixing was done in en 
bloc on the pelleted cells using 1% osmium tetroxide with 2% aqueous uranyl acetate. 
Dehydration of the pelleted cells was accomplished by treatment with solutions of 
increasing ethanol content (100% final). The dehydrated pellet was then embedding 
by solutions of propylene oxide with increasing Spurr’s resin content (100% final) 
and curing at 70°C overnight. Expressed VLPs were visualized in whole fixed 
bacterial cells and in purified form using a transmission electron microscope at 80 
kV. 
 VLP surface assembly and electroless plating 4.2.3.
 Purified TMV-VLP1cys was self-assembled onto 1 cm2 gold-coated silicon 
chips by incubation overnight at 4°C in a 1 mg/mL solution of the purified VLPs 
resuspended in 0.1 mM sodium phosphate buffer, pH 7. VLP assembled chips were 
then dipped in a 0.158 mM solution of Na2PdCl4 for 30 minutes at 4°C. The surface-
bound VLPs were then coated with nickel by moving the chip directly into an 
electroless nickel plating solution consisting of 0.05 M NiCl2, 0.12 M glycine, 0.0785 
M sodium tetraborate, 0.525 M dimethylamine borane complex at pH 7. Nickel 
deposition by reduction was allowed to proceed at room temperature until the entire 






 Chip based enzyme-linked immunosorbent assay (ELISA) 4.2.4.
 Gold coated 1cm2 silicon nitrate chips were submerged overnight in purified 
TMV1cys-VLP or TMV1cys-VLP1cys-FLAG at 4°C to facilitate oriented VLP 
assembly onto the gold surface. VLP assembled chips were then incubated for an 
additional 30 min at 4°C in Tris buffered saline (50 mM Tris-HCL, 200 mM NaCl, 
TBS) pH 7.0 containing 5% non-fat dry milk as a blocking agent. Chips were then 
rinsed three times by submersion in fresh TBS buffer. Rinsed chips were 
subsequently incubated for 3 hrs at room temperature in TBS containing 5% non-fat 
dry milk and a 1/1000 dilution of rabbit anti-flag antibody (Sigma-Aldrich, St. Louis 
MO). The chip was then rinsed 3 times with TBS buffer and twice with TBS buffer 
containing 0.05% Tween-20. After rinsing, chips were submerged in TBS with 5% 
nonfat dry milk containing a 1/5000 dilution of anti-rabbit IgG alkaline phosphatase 
and incubated at room temperature for 3 hrs. Chips were again rinsed as described 
above and placed directly in a solution containing 0.15 mg/ml of 5-bromo-4-chloro-3-
indoyl phosphate and 0.3 mg/ml NitroBT in substrate buffer (10 mM Tris-HCL pH 
9.5, 100 mM NaCl and 5 mM MgCl-6H2O) and incubated for 10 min at room 
temperature. The reaction was stopped by immersion in water and the chips dried. 
Color intensities of individual chips were measured using ImageJ software [167].  
 Fluorescence binding onto IQ peptide tagged TMV-VLPs 4.2.5.
 The IQ-tag modified VLPs were tested for preferential binding of the 
fluorescent imaging agent GenhanceTM 680 (PerkinElmer, Waltham MA) as follows. 
Purified TMV1cys-VLP-AmberFlex-IQ (0.2 mg/ml or 0.02 mg/ml) were incubated 





addition of 10 μL of 0.1 mg/mL GenhanceTM 680. Samples were then centrifuged at 
16,000 × g for 45 min. The VLP pellets were then resuspended in 1 mL of 0.1 M pH 
7.0 phosphate buffer and centrifuged again for 45 min. Pelleted VLPs were then 
resuspended in 0.1 M pH 7.0 phosphate buffer to a concentration of 0.5 mg/mL and 
0.05 mg/mL. 200 μL of each sample was added to a black-walled 96-well microtiter 
plate and fluorescence intensity at 690 nm (655 nm excitation and a 665 nm cutoff) 
was determined using a SpectraMax M2 (Molecular Devices, Sunnyvale, CA).  
 Design of modified TMV CP genes  4.2.6.
The TMV capsid protein gene was modified to substitute neutrally charged or 
basic amino acid residues for one or more of the negatively charged acidic residues 
which interact with those on adjacent CP subunits. All modified forms of the TMV 
capsid protein used in this study were ultimately generated from copies of a DNA 
open reading frame (ORF) encoding the TMV CP codon optimized for expression in 
E. coli using codon utilization frequency tables. The ORF encoding the E50Q/D77N 
form was obtained from GenScript (Piscataway, NJ). The ORFs encoding the 
E95Q/E97Q/E106Q/D109N, E50Q+E95Q/E97Q/D109N, D77N+E106Q, E50K-HA, 
and D77H and R46G-E50H-HA were generated using Invitrogen™ GeneArt™ 
Strings™ DNA fragments. All additional variants were generated by sequential 
polymerase chain reactions using overlap extension PCR with primers encoding the 
designed modifications and complimentary to regions of the ORF to be modified. 
These included additional modifications to the carboxylate-containing sites E50, D77, 
E95, E97, E106, and E109, the insertion of the S1_Y2insC (hereafter denoted as 





MSCYS…), and insertion or replacement of sequences encoding either the FLAG-tag 
epitope (DYKDDDDK) or the HA-tag (YPYDVPDYA) to the 3ʹ end of the gene, 
following the sequence encoding the C-terminal PAT residues. Two endonuclease 
restriction sites, an NdeI restriction site over lapping the ORF start codon and an XhoI 
restriction site at the 3ʹ end, flanking the ORF were included. For each ORF-interior 
modification, a set of PCR reactions, each using a primer pair consisting of either a 
forward primer containing the ORF 5ʹ end and a reverse primer containing the interior 
modification or a forward primer containing the interior modification and a reverse 
primer containing the ORF 3ʹ end, was performed using Platinum Taq DNA 
Polymerase (Invitrogen): 94 °C for 5min; 32 cycles of 94 °C for 30 s / 55 °C for 30 s / 
72 °C for 1 min; 72 °C for 5 min). The PCR product from each of the two PCR 
reactions was gel-purified using a GENECLEAN III gel purification kit (MP 
Biomedicals) and used as templates for PCR with the 5ʹ end forward primer and the 3ʹ 
end reverse primer from the previous PCR reactions. Complete PCR products of CP 
ORFs were isolated and amplified using a TOPO TA cloning kit. pCR-2.0 vector, 
TOP10 competent cells (Invitrogen). 
ORFs were excised from TA clones by restriction with NdeI and XhoI and 
isolated from the plasmid vector by agarose gel electrophoresis. Bands were purified 
using GENECLEAN III gel purification kit and purified DNA fragments were ligated 
into a similarly cut and purified pET-21a(+) (Novagen, Madison, WI) or pET-DUET 
expression vector with T4 DNA ligase. Complimentary overhangs between vector 
and insert were created by using the same restriction enzymes. Ligated plasmid 





for amplification with ampicillin selection and subsequent miniprep purification. 
Clones containing inserted genetic material were identified using restriction 
hydrolysis of ORF-flanking restriction sites and were sequenced to screen for 
unintended mutations.  
 Bacterial expression and purification of TMV CP variants 4.2.7.
 Plasmids containing sequence-verified ORFs encoding the various TMV CPs 
described above were transformed into chemically competent BL21-CodonPlus E. 
coli K-12 cells. Transformations were spread onto LB-agar plates containing 
ampicillin (100 µg/mL) and chloramphenicol (20 µg/mL). Colonies were picked and 
grown in LB containing ampicillin (100 µg/mL) and chloramphenicol (20 µg/mL) at 
37 °C overnight. Frozen stocks of cells containing the TMV CP constructs for 
continued production of modified CP were made by addition of DMSO (70 µl/mL 
culture) and storage at -80 °C. Cell cultures were grown at 37 °C until reaching an 
absorbance of 0.5 ± 0.1 at a wavelength of 600 nm. At that point the culture was 
induced by the addition of IPTG to a concentration of 1 mM and incubated at room 
temperature with shaking overnight. Induced cells were pelleted by centrifugation at 4 
°C and lysed by resuspension in Bugbuster HT Protein Extraction Reagent and the 
addition of Lysonase according to the manufacturer’s protocol (Novagen, Madison 
WI) and incubation at room temperature for 30 minutes. The bacterial lysate was 
diluted 10:1 with 0.1 M pH 7 phosphate buffer and pelleted by centrifugation at 
91,000 × g for 2 hours. The resulting pellet was resuspended in 2 mL 0.1 M pH 7 
phosphate buffer with pipetting and shaking overnight at 4°C. Resuspended pellets 





centrifuged at 91,000 × g at 14 °C for either 1 hour (E50Q and D77N variants) or 15 
minutes (E50K and D77K variants). The virus-like particles were removed from the 
center portion of the gradient, where they formed a diffuse visible band, with a 
syringe and transferred to ~25 mL ultracentrifuge tubes. The samples were diluted 
with 0.1 M pH 7 phosphate buffer to reduce sucrose concentration and centrifuged at 
91,000 × g for 2 hours at 4 °C. The purified VLP pellets were resuspended in 0.1 M 
pH 7 phosphate buffer. 
 Determining concentration of TMV and bacterially expressed 4.2.8.
TMV CP 
 All determinations of disassembled CP and assembled VLP solution 
concentrations were made using a Thermo Fisher Scientific™ Nanodrop™ 1000. 
VLP samples purified from monoclonal cultures of transformed expression strains of 
E. coli (BL21 and BL21 codon plus) all showed a light attenuation peaks at around 
280 nm, indicating the relative lack of nucleic acid and in contrast to purified samples 
of absorption spectrum of encapsidated RNA centered around 260 nm. 
 Determinations of TMV concentrations, which contain the genomic RNA, 
were made by measuring the attenuation of the TMV sample at λ = 260 nm, 
calculating and subtracting the attenuation due to scattering to obtain the attenuation 
at 260 nm attributable to absorbance alone and using the mass attenuation coefficient 
and path length to determine concentration using the following form of the Beer-
Lambert law 
𝐶𝐶 =







Where A260 and A325 are the sample absorption measurements of 260 nm and 325 nm 
wavelength light, respectively, εTMV,260 is the extinction/attenuation coefficient of 
TMV at wavelength 260 nm, and l is the path length. The expression 2.44 × A325 is 
the estimated attenuation at 260 nm due to scattering. Because neither protein nor 
RNA has significant absorption at 325 nm, all attenuation at 325 nm is assumed to be 
due to scattering. Because scattering varies with wavelength with a factor of λ−4,the 
scattering at 260 nm is related to the scattering at 325 nm by a factor of (260−4/325−4) 
= 2.44. The inherited mass attenuation coefficient for TMV, ε260, is 3 L∙g−1∙cm−1. 
 The concentration of RNA-free, bacterially expressed CP was determined by 
measuring the optical attenuation at λ = 280 nm, calculating and subtracting the 
attenuation due to scattering to obtain the attenuation  at 280 nm attributable to 
absorbance alone and using the mass attenuation coefficient and path length to 
determine concentration using the following form of the Beer-Lambert law 
𝐶𝐶 =  
𝐴𝐴280  −  (1.8 ×  𝐴𝐴325)
𝜀𝜀𝐶𝐶𝐶𝐶,280  ×  𝑙𝑙
 
Where A280 and A325 are the sample absorption measurements of 280 nm and 325 nm 
wavelength light, respectively, ε280, is the extinction/attenuation coefficient of the 
relevant CP at wavelength 260 nm (see table), and l is the path length. The expression 
1.8 × A325 is the estimated attenuation at 280 nm due to scattering. Because protein 
does not have significant absorption at 325 nm, all attenuation at 325 nm is assumed 
to be due to scattering. Because scattering varies with wavelength with a factor of 
λ−4,the scattering at 280 nm is related to the scattering at 325 nm by a factor of 





 The attenuation coefficients of the VLP-forming CPs were calculated using 
the Edelhoch method, according to which 
𝜀𝜀(208)(𝑀𝑀−1𝑐𝑐𝑐𝑐−1) = (#𝑇𝑇𝑇𝑇𝑇𝑇)(5,500) + (#𝑇𝑇𝑇𝑇𝑇𝑇)(1,490) + (#𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑙𝑙𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑)(125) 
where ε(280) is the molar attenuation coefficient, #Trp, #Tyr, and #disulfide are the 
number of tryptophan residues, tyrosine residues, and disulfide bonds bonds formed 
by crosslinked cysteine residues, respectively. The corresponding mass attenuation 
coefficients were obtained by dividing the molar attenuation coefficents by the mass 
in grams per mole of CP.  






Molar ε  
(M−1∙cm−1) 
FW Mass ε  
(L∙g−1∙cm−1) 
WT CP 3 4 0 22460 17420 1.289 
1cys CP 3 4 0 22460 17524 1.281 
R46G/E50K-
E97Q-FLAG 
3 6 0 25440 18405 1.382 
D77K-HA 3 5 0 23950 18429 1.299 
Table 5: Molar and mass attenuation coefficients at 280 nm for various TMV CPs. 
 Longitudinal coassembly of neutral carboxylate-substituted 4.2.9.
CP variants with TMV or VLP with wild-type axial 
carboxylates 
 Complexed nanoparticles with distinct and ordered longitudinal domains 
generated from the coassembly of a nanoparticle retaining wild-type axially 
interacting carboxylate residues (either infectious TMV or VLP assembled from 
E95Q/E97Q/D109N+E106Q CP) together with a VLP containing uncharged amino 
acids substituted at one rod end (E50Q+E95Q/E97Q/D109N-FLAG VLP or 
D77N+E106-HA VLP) were produced by concentration of a solution containing a 





 For the longitudinal coassembly of TMV and D77N+E106Q-HA VLP, 100 µg 
each of purified 5 mg/mL 1cys TMV and D77N+E106Q-HA VLP in 0.1 M pH 7 
sodium phosphate buffer were mixed and diluted with 25 mL 0.1 M pH 7 sodium 
phosphate buffer in a ultracentrifuge tube. The mixture was centrifuged at 91,000 × g 
for 2 hours at 4 °C, at which point the supernatant was removed and replaced with 
100 µL of 0.1 M pH 7 sodium phosphate buffer. The pellet was allowed to resuspend 
overnight at 4 °C with gentle rocking, then diluted (1:500) in 0.1 M pH 7 phosphate 
buffer for immunolabelling and preparation for TEM. 
For the longitudinal coassembly of E95Q/E97Q/D109N+E106Q VLP with 
 E50Q+E95Q/E97Q/D109N-FLAG VLP, 50 µL of 1 mg/mL solutions of each 
of the two purified VLPs in 0.01 M pH 7 sodium phosphate buffer were well mixed 
in a 1.5 mL centrifuge tube. The mixed sample was then centrifuged under partial 
vacuum until the sample volume had reduced to ~10 µL (approximately one hour). 
The concentrated sample was kept at 4 °C overnight before dilution (1:500) in 0.1 M 
pH 7 sodium phosphate buffer for immunolabelling and preparation for TEM. 
 Dialysis of samples 4.2.10.
 All dialysis was performed Spectra/Por® dialysis membrane tubing 
(MWCO:12-14,000, Spectrum Labs) secured to the opening of a 1.5 mL 
microcentrifuge tube containing 50-200 µL of plant-expressed TMV and/or 
bacterially expressed CP. The microcentrifuge tubes were inverted so that sample 
solution was in contact with dialysis film and placed in a floating microcentrifuge 
holder on the surface of 500 mL of the solution to be dialyzed against, so that the 





performed at 4 °C overnight. For all dialysis experiments, TMV or CP samples, 
which were initially in 0.1 M pH 7 sodium phosphate buffer were first dialyzed to 0.1 
M pH 7 Tris buffer. The pH 7 Tris-buffered samples were then dialyzed against either 
ultrapure water adjusted to pH 7 with approximately 50 µL of 12 M NaOH per 1 L of 
water or 0.1 M Tris adjusted to pH 5, 6, 7, 8, or 9 with glacial HCl or 12 M NaOH. 
 Longitudinal coassembly of positively-charged carboxylate-4.2.11.
substituted CP variants with TMV 
 To generate extended TMV-VLP complexed particles with distinct and 
ordered longitudinal components, TMV and VLP were dialyzed either separately or 
in admixture to solution conditions promoting disassembly of the VLP CP and then 
returned to conditions promoting its assembly, either by dialysis or by the addition of 
concentrated solution.  
 For assembly of D77K-HA CP onto TMV, 50 µL of a solution containing 3 
mg/mL of D77K-HA CP and 0.6 mg/mL wild-type TMV (a ratio of 5:1 by mass) in 
0.1 M pH 7 sodium phosphate buffer was dialyzed as described above first to 0.1 M 
pH 7 Tris buffer, then to 0.1 M pH 9 Tris buffer to disassemble the D77K CP, and 
then to 0.1 M pH 7 Tris buffer to initiate reassembly of the D77K CP onto the TMV 
rod end with each dialysis step taking place overnight at 4 °C. For samples treated 
with RNase, 0.5 µL of a 1 mg/mL stock solution of RNase A was added to the 
solution after the dialysis to pH 9, which was hypothesized to have exposed the 
genomic RNA at the TMV’s 5ʹ rod end, and incubated for 30 min at 37 °C before 





 For assembly of R46G/E50K+E97G-FLAG CP onto TMV, 50 µL of a 
solution containing 1 mg/mL of R46G/E50K+E97G-FLAG and 0.5 mg/mL wild-type 
TMV (a ratio of 2:1 by mass) in 0.1 M pH 7 sodium phosphate buffer was dialyzed 
first to 0.1 M pH 7 Tris buffer, then to filtered ultrapure water brought to pH 7 with 
NaOH to disassemble the R46G/E50K+E97G CP, and then to 0.1 M pH 7 Tris buffer 
/ 0.3 M NaCl to initiate reassembly of R46G/E50K+E97G CP onto the TMV rod end 
with each dialysis step taking place overnight at 4 °C. 
 Immunolabelling and electron microscopy 4.2.12.
 To immunolabel and image samples, assembled TMV and VLP samples were 
adsorbed onto Formvar-coated Ni TEM grids by floating the grid on 5-10 µL droplets 
containing the sample arrayed on Parafilm™. Grids were washed with phosphate-
buffered saline (PBS: 10 mM sodium phosphate, 150 mM NaCl, pH 7). Surfaces were 
blocked with Blocking Solution for Goat Antibodies (Aurion, Wageningen, The 
Netherlands) to reduce nonspecific binding and washed with PBS. Primary antibodies 
(anti-FLAG antibodies produced in rabbit, anti-HA antibodies produced in mouse, 
Sigma) were diluted 1:500 in incubation buffer (PBS with 0.1% Tween-20 and 0.1% 
Aurion BSA-c™) as needed and applied to grids at room temperature for 2 h or at 4 
°C overnight. Grids were washed by placing on 50 µL drops of incubation buffer for 
5 min three times. Gold nanoparticle (AuNP)-conjugated secondary antibodies (i.e. 
goat anti-rabbit with 10 nm AuNPs or goat anti-mouse with 6 nm AuNPs), if used, 
were diluted 1:50 in incubation buffer as needed and applied to grids at room 
temperature for 2 h or at 4 °C overnight. Grids were washed by placing on 50 µL 





M pH 7 Tris. Grids were stained by placing them on a 5 µL droplet of 2% uranyl 
acetate (UAc) for 1 min. UAc was removed by wicking with filter paper, and the 
samples were imaged using a Zeiss transmission electron microscope (TEM) at 80 
kV. 
 Light scattering assembly kinetics 4.2.13.
Macromolecular assembly kinetics of the D77K and R46G/E50K+E97G CP 
from the disassembled to the assembled state upon lowering of the pH or increase of 
the ionic strength of the solution was observed in real time using 90° light scattering 
to measure the relative degree of rod formation in an aqueous solution of CP. Light 
scattering was measured on a Varian Cary Eclipse Fluorescence Spectrophotometer. 
Scattered light was measured at an angle of 90° relative to the angle of incidence 
using 200 µL of CP solution in a 200 µL capacity quartz cuvette and using the same 
value of 340 nm for the excitation and emission wavelengths. The dissociation factor 
D was related to the intensity of scattered light, I, by 
𝐷𝐷 = (𝐼𝐼𝐴𝐴 − 𝐼𝐼)/(𝐼𝐼𝐴𝐴 − 𝐼𝐼𝐷𝐷) 
where IA and ID are the intensity of scattered light for associated and dissociated 
forms, respectively. 
 For experiments examining D77K CP assembly, samples were measured by 
beginning recording of scattered light with baseline measurement of 175 µL of 0.1 M 
Tris buffer adjusted to pH 5. After 30 s, 25 µL of D77K-HA-tag CP previously 
dialyzed against 0.1 M Tris buffer adjusted to pH 9 was added and mixed by manual 
pipetting. Light scattering was recorded for 20 minutes after mixing. 





measured by beginning recording of scattered light with baseline measurement of 100 
µL of R46G/E50K+E97G-FLAG-tag CP previously dialyzed against filtered water 
adjusted to pH 7 with NaOH (~50 μL 12 M NaOH / 1 L H2O). After 30 s, 100 µL of 
0.2 M Tris buffer with 0.6 M NaCl adjusted to pH 9 was added and mixed by manual 
pipetting. Light scattering was recorded for 30 minutes after mixing. 
Data was obtained using 340 nm as both the “excitation” (incident light applied to 
sample from the light source) and “emission” (scattered light measured from sample) 
wavelength values. This wavelength was chosen after several experiments in which a 
scan of excitation and emission values were covaried through a range from 200 nm to 
700 nm every minute during an assembly reaction of D77K-HA CP. Significant 
changes in scattered light was observed in the ranges from ~240 nm to ~270 nm and  
from ~280 nm up to 700 nm, with a dramatically reduced level of scattering observed 
in the region around 280 nm, presumably due to the high level of absorption by 
sample CP. The wavelength 340 nm was selected from the candidate ranges as 
determined by observation due to its use in the literature as a value previously used to 
study the assembly state of TMV [197, 198]. 
 Surface-bound fabrication of co-assembled nanoparticles 4.2.14.
Gold-coated silica wafers (0.5 cm × 0.5 cm), cleaned by sequential 5 min 
submersions in acetone, methanol, and isopropanol with agitation, were submerged in 
either a 0.2 mg/mL solution of 1cys TMV in 0.1 M pH 7 sodium phosphate buffer or 
0.1 M pH 7 sodium phosphate buffer containing no virus overnight at 4 °C. Residual 
phosphate buffer was removed by submersion of the wafers in either 0.1 M pH 9 Tris 





addition of ~50 μl 12 M NaOH /  1 L water using a pH-meter to monitor pH level) for 
subsequent addition of R46G/E50K+E97G-FLAG CP. 
For longitudinal coassembly of D77K-HA CP onto the TMV base layer: The 
wafers were placed gold-side-up on Parafilm™ in a 60 mm diameter petri dish. 5 μL 
of either 0.1 M pH 9 Tris or a 5 mg/ mL solution of D77K-HA CP previously 
dialyzed with 0.1 M pH 9 Tris to promote VLP disassembly was added to the gold 
surface by pipet and allowed to sit for 10 minutes at room temperature. Then 35 μL 
0.1 M pH 5 Tris buffer was transferred to the gold surface by pipet, and the petri dish 
was covered with the lid and transferred to 4 °C overnight.  
For longitudinal coassembly of R46G/E50K+E97G-FLAG CP onto the TMV 
base layer: The wafers were placed gold-side-up on Parafilm™ in a 60 mm diameter 
petri dish. 10 μL of either filtered water adjusted to pH7  or a 10 mg/ mL solution of 
R46G/E50K+E97G-FLAG CP previously dialyzed with filtered water adjusted to 
pH7 to promote VLP disassembly was added to the gold surface by pipet and allowed 
to sit for 10 minutes at room temperature. Then 10 μL 0.6 M NaCl, 0.2 M pH 7 Tris 
buffer was transferred to the gold surface by pipet, and the petri dish was covered 
with the lid and transferred to 4 °C overnight.  
Excess unbound CP was washed by submersion of the wafers in 1 mL 0.1 M 
pH 7 Tris (for D77K-HA CP samples) or 1 mL 0.3 M NaCl, 0.1 M pH 7 Tris (for 
R46G/E50K+E97G-FLAG CP samples) for 5 minutes. The wafers were then placed 
gold-side-up on Parafilm™ in a 60 mm diameter petri dish, and a 50 μL droplet of 
Aurion Blocking Solution for Goat Antibodies was gently layered onto each wafer 





of the wafers in 1 mL 0.1 M pH 7 Tris (for D77K-HA CP samples) or 1 mL 0.3 M 
NaCl, 0.1 M pH 7 Tris (for R46G/E50K+E97G-FLAG CP samples) for 5 minutes, 3 
times. The wafers were again transferred to Parafilm™, and 50 μL of primary 
antibodies (anti-FLAG antibodies produced in rabbit, anti-HA antibodies produced in 
mouse, Sigma) diluted 1:1000 in incubation buffer (PBS with 0.1% Tween-20 and 
0.1% Aurion BSA-c™) was applied to each wafer at room temperature for 2 h or at 4 
°C overnight. The wafers were again washed 3 times for 5 minutes each in 1 mL 0.1 
M pH 7 Tris (for D77K-HA CP samples) or 1 mL 0.3 M NaCl, 0.1 M pH 7 Tris (for 
R46G/E50K+E97G-FLAG CP samples). The wafers were then submerged in 500 μL 
of a 1:1000 solution of secondary antibodies conjugated to horseradish peroxidase 
(anti-rabbit antibodies produced in goat in 0.1 M pH 7 Tris for D77K-HA CP samples 
and anti-mouse antibodies produced in goat in 0.3 M NaCl, 0.1 M pH 7 Tris for 
R46G/E50K+E97G-FLAG CP samples. The wafers were again washed 3 times for 5 
minutes each in 1 mL 0.1 M pH 7 Tris (for D77K-HA CP samples) or 1 mL 0.3 M 
NaCl, 0.1 M pH 7 Tris (for R46G/E50K+E97G-FLAG CP samples). The wafers were 
then submerged in 1 mL substrate buffer (0.1 M pH 7 Tris, 0.2 M NaCl and 5 mM 
MgCl) containing 0.15 mg/ml of 5-bromo-4-chloro-3-indoyl phosphate and 0.3 
mg/ml NitroBT. The submerged wafers were monitored for color change, and all 
wafers were removed and washed with 0.3 M NaCl, 0.1 M pH 7 Tris to halt 
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